

 



<!DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Transitional//EN"
  "http://www.w3.org/TR/xhtml1/DTD/xhtml1-transitional.dtd">
<html xmlns="http://www.w3.org/1999/xhtml"
      xmlns:foaf="http://xmlns.com/foaf/0.1/"
      xmlns:dc="http://purl.org/dc/terms/"
      xmlns:doi="http://dx.doi.org/"
      xmlns:rdf="http://www.w3.org/1999/02/22-rdf-syntax-ns#"
      xmlns:xsd="http://www.w3.org/2001/XMLSchema-datatypes#"
      lang="en" xml:lang="en"
      itemscope itemtype="http://schema.org/Article"
      class="no-js">
<head prefix="og: http://ogp.me/ns#">
  <title>PLOS ONE: Anti-Tuberculosis Therapy-Induced Hepatotoxicity among Ethiopian HIV-Positive and Negative Patients</title>


<link rel="stylesheet" type="text/css"  href="/css/global-min.css?v=izteQ6tu7kgsJZW_xmrYizvKiHM" />


    <!--[if lte IE 7]>
<link rel="stylesheet" type="text/css"  href="/css/lte_ie7-min.css?v=3bykQUyQmReeuobVyPozcJ9LxRc" />
    <![endif]-->


<link rel="stylesheet" type="text/css"  href="/css/jquery-ui-min.css?v=eXDHTEJM0lIAmDe5k0I0Ad4nxNo" />


<link rel="stylesheet" type="text/css"  href="/css/journal.css?v=T7ZVxJfgk9jNxLAJ2qHz1vZpgYU" />


<link rel="stylesheet" type="text/css" media="print" href="/css/print-min.css?v=T5lb0B3q6EXBsuDluc5V5w+AkRc" />


  <link rel="stylesheet" href="http://f.fontdeck.com/s/css/js/www.plosone.org/24557.css" type="text/css"/>

  <!--chartbeat -->
  <script type="text/javascript">var _sf_startpt = (new Date()).getTime()</script>
  <script>document.documentElement.className += ' js';</script>

  <meta http-equiv="Content-Type" content="text/html; charset=utf-8"/>
  <meta http-equiv="X-UA-Compatible" content="IE=EmulateIE7; IE=EmulateIE9"/>
  <meta name="description" content="PLOS ONE: an inclusive, peer-reviewed, open-access resource from the PUBLIC LIBRARY OF SCIENCE. Reports of well-performed scientific studies from all disciplines freely available to the whole world."/>
  <meta name="keywords" content="PLOS, Public Library of Science, Open Access, Open-Access, Science, Medicine, Biology, Research, Peer-review, Inclusive, Interdisciplinary, Ante-disciplinary, Physics, Chemistry, Engineering"/>
  <meta name="almHost" content="http://alm.plos.org/api/v3/articles"/>
  <meta name="searchHost" content="http://api.plos.org/search" />
  <meta name="termsHost" content="http://api.plos.org/terms" />
  <meta name="solrApiKey" content="plos"/>
  <meta name="almAPIKey" content="3pezRBRXdyzYW6ztfwft" />
  <meta name="currentJournal" content="PLoSONE" />
  <meta name="almRequestBatchSize" content="" />

  <meta name="citation_publisher" content="Public Library of Science"/>
  <meta name="citation_doi" content="10.1371/journal.pone.0001809"/>
  <meta name="dc.identifier" content="10.1371/journal.pone.0001809" />

    <meta name="citation_title" content="Anti-Tuberculosis Therapy-Induced Hepatotoxicity among Ethiopian HIV-Positive and Negative Patients"/>
    <meta itemprop="name" content="Anti-Tuberculosis Therapy-Induced Hepatotoxicity among Ethiopian HIV-Positive and Negative Patients"/>

      <meta name="citation_author" content="Getnet Yimer"/>
            <meta name="citation_author_institution" content="Armauer Hansen Research Institute, Addis Ababa, Ethiopia"/>
            <meta name="citation_author_institution" content="Addis Ababa University, Medical Faculty, Addis Ababa, Ethiopia"/>
      <meta name="citation_author" content="Getachew Aderaye"/>
            <meta name="citation_author_institution" content="Addis Ababa University, Medical Faculty, Addis Ababa, Ethiopia"/>
      <meta name="citation_author" content="Wondwossen Amogne"/>
            <meta name="citation_author_institution" content="Addis Ababa University, Medical Faculty, Addis Ababa, Ethiopia"/>
      <meta name="citation_author" content="Eyasu Makonnen"/>
            <meta name="citation_author_institution" content="Addis Ababa University, Medical Faculty, Addis Ababa, Ethiopia"/>
      <meta name="citation_author" content="Eleni Aklillu"/>
            <meta name="citation_author_institution" content="Department of Clinical Pharmacology, Karolinska Institute, Stockholm, Sweden"/>
      <meta name="citation_author" content="Lars Lindquist"/>
            <meta name="citation_author_institution" content="Department of Internal Medicine, Infectious Disease Unit, Karolinska Institute, Stockholm, Sweden"/>
      <meta name="citation_author" content="Lawrence Yamuah"/>
            <meta name="citation_author_institution" content="Armauer Hansen Research Institute, Addis Ababa, Ethiopia"/>
      <meta name="citation_author" content="Beniyam Feleke"/>
            <meta name="citation_author_institution" content="St. Peter's TB Specialized Hospital, Addis Ababa, Ethiopia"/>
      <meta name="citation_author" content="Abraham Aseffa"/>
            <meta name="citation_author_institution" content="Armauer Hansen Research Institute, Addis Ababa, Ethiopia"/>

    <meta name="citation_date" content="2008/3/19"/>

  <meta name="citation_pdf_url" content="http://dx.plos.org/10.1371/journal.pone.0001809.pdf" />

      <meta name="citation_journal_title" content="PLOS ONE" />
    <meta name="citation_firstpage" content="e1809"/>
    <meta name="citation_issue" content="3"/>
    <meta name="citation_volume" content="3"/>
    <meta name="citation_issn" content="1932-6203"/>

    <meta name="citation_journal_abbrev" content="PLoS ONE" />

      <meta name="citation_reference" content="citation_title=Consensus statement. Global burden of tuberculosis: estimated incidence, prevalence, and mortality by country. WHO Global Surveillance and Monitoring Project.; citation_author=C Dye; citation_author=S Scheele; citation_author=P Dolin; citation_author=V Pathania; citation_author=MC Raviglione; citation_journal_title=JAMA; citation_volume=282; citation_number=1; citation_pages=677-686; citation_date=1999; " />
      <meta name="citation_reference" content="citation_title=Tuberculosis: medical management update.; citation_author=JF Yepes; citation_author=J Sullivan; citation_author=A Pinto; citation_journal_title=Oral Surg Oral Med Oral Pathol Oral Radiol Endod; citation_volume=98; citation_number=2; citation_pages=267-273; citation_date=2004; " />
      <meta name="citation_reference" content="citation_title=To control and beyond: moving towards eliminating the global tuberculosis threat.; citation_author=TF Brewer; citation_author=J Heymann; citation_journal_title=J Epidemiol Community Health; citation_volume=58; citation_number=3; citation_pages=822-825; citation_date=2004; " />
      <meta name="citation_reference" content="citation_title=Tuberculosis in HIV-infected patients: a comprehensive review.; citation_author=L Aaron; citation_author=D Saadoun; citation_author=I Calatroni; citation_author=O Launay; citation_author=N Emain; citation_journal_title=Clin Microbiol Infect; citation_volume=10; citation_number=4; citation_pages=388-398; citation_date=2004; " />
      <meta name="citation_reference" content="citation_title=The trend of pulmonary tuberculosis in patients seen at DOTS clinics in the Federal Capital Territory, Abuja, Nigeria.; citation_author=EB Bassey; citation_author=MA Momoh; citation_author=SO Imadiyi; citation_author=EB Udofia; citation_author=FS Miri; citation_journal_title=Public; citation_volume=Health119; citation_number=5; citation_pages=405-408; citation_date=2005; " />
      <meta name="citation_reference" content="citation_title=Tuberculosis and HIV. Current American Thoracic Society/CDC Treatment Recommendation.; citation_author=L Gooze; citation_number=6; citation_date=2003; " />
      <meta name="citation_reference" content="citation_title=Tuberculosis.; citation_journal_title=Nature reviews/microbiology; citation_volume=2; citation_number=7; citation_pages=930-932; citation_date=2004; " />
      <meta name="citation_reference" content="citation_title=TB/HIV A CLINICAL MANUAL; citation_number=8; citation_date=2004; " />
      <meta name="citation_reference" content="citation_title=Hepatotoxic effects of tuberculosis therapy. A practical approach to a tricky management problem.; citation_author=J Ali; citation_journal_title=Postgrad Med; citation_volume=99; citation_number=9; citation_pages=217-220; citation_date=1996; " />
      <meta name="citation_reference" content="citation_title=MONITORING FOR HEPATOTOXICITY DURING ANTITUBERCULOSIS TREATMENT; citation_author=T Cheuk-ming; citation_number=10; citation_date=2002; " />
      <meta name="citation_reference" content="citation_title=Cytochrome P450 2E1 genotype and the susceptibility to antituberculosis drug-induced hepatitis.; citation_author=YS Huang; citation_author=HD Chern; citation_author=WJ Su; citation_author=JC Wu; citation_author=SC Chang; citation_journal_title=Hepatology; citation_volume=37; citation_number=11; citation_pages=924-930; citation_date=2003; " />
      <meta name="citation_reference" content="citation_title=Evaluation of clinical and immunogenetic risk factors for the development of hepatotoxicity during antituberculosis treatment.; citation_author=SK Sharma; citation_author=A Balamurugan; citation_author=PK Saha; citation_author=RM Pandey; citation_author=NK Mehra; citation_journal_title=Am J Respir Crit Care Med; citation_volume=166; citation_number=12; citation_pages=916-919; citation_date=2002; " />
      <meta name="citation_reference" content="citation_title=Antituberculosis drug-induced hepatotoxicity. The role of hepatitis C virus and the human immunodeficiency virus.; citation_author=JR Ungo; citation_author=D Jones; citation_author=D Ashkin; citation_author=ES Hollender; citation_author=D Bernstein; citation_journal_title=Am J Respir Crit Care Med; citation_volume=157; citation_number=13; citation_pages=1871-1876; citation_date=1998; " />
      <meta name="citation_reference" content="citation_title=Sputum concentration improves diagnosis of tuberculosis in a setting with a high prevalence of HIV.; citation_author=J Bruchfeld; citation_author=J Bruchfeld; citation_author=G Aderaye; citation_author=IB Palme; citation_author=B Bjorvatn; citation_author=G Kallenius; citation_journal_title=Trans R Soc Trop Med Hyg; citation_volume=94; citation_number=14; citation_pages=677-680; citation_date=2000; " />
      <meta name="citation_reference" content="citation_title=Antituberculous drugs in patients with chronic liver disease.; citation_author=E Kimmoun; citation_author=D Samuel; citation_journal_title=J Gastroenterol Hepatol; citation_volume=17; citation_number=15; citation_pages=S408-S412; citation_date=2002; " />
      <meta name="citation_reference" content="citation_title=Tuberculosis in the 1990s.; citation_author=PF Barnes; citation_author=SA Barrows; citation_journal_title=Ann Intern Med; citation_volume=119; citation_number=16; citation_pages=400-410; citation_date=1993; " />
      <meta name="citation_reference" content="citation_title=Isoniazid-induced hyperacute liver failure in a young patient receiving carbamazepine.; citation_author=JA Campos-Franco; citation_author= Gonzalez-Quintela; citation_author=MR Alende-Sixto; citation_journal_title=Eur J Intern Med; citation_volume=15; citation_number=17; citation_pages=396-397; citation_date=2004; " />
      <meta name="citation_reference" content="citation_title=Hepatotoxicity from isoniazid and rifampin in inner-city AIDS patients.; citation_author=LA Ozick; citation_author=L Jacob; citation_author=GM Comer; citation_author=TP Lee; citation_author=J Ben-Zvi; citation_journal_title=Am J Gastroenterol; citation_volume=90; citation_number=18; citation_pages=1978-1980; citation_date=1995; " />
      <meta name="citation_reference" content="citation_title=Distribution and concordance of N-acetyltransferase genotype and phenotype in an American population.; citation_author=M Gross; citation_author=T Kruisselbrink; citation_author=K Anderson; citation_author=N Lang; citation_author=P McGovern; citation_journal_title=Cancer Epidemiol Biomarkers Prev; citation_volume=8; citation_number=19; citation_pages=683-692; citation_date=1999; " />
      <meta name="citation_reference" content="citation_title=Efficacy and safety of Efavirenz in HIV patients on Rifampin for tuberculosis.; citation_author=DB Pedral-Sampaio; citation_author=CR Alves; citation_author=EM Netto; citation_author=C Brites; citation_author=AS Oliveira; citation_journal_title=Braz J Infect Dis; citation_volume=8; citation_number=20; citation_pages=211-216; citation_date=2004; " />
      <meta name="citation_reference" content="citation_title=Incidence of serious side effects from first-line antituberculosis drugs among patients treated for active tuberculosis.; citation_author=D Yee; citation_author=C Valiquette; citation_author=M Pelletier; citation_author=I Parisien; citation_author=I Rocher; citation_journal_title=Am J Respir Crit Care Med; citation_volume=167; citation_number=21; citation_pages=1472-1477; citation_date=2003; " />
      <meta name="citation_reference" content="citation_title=HIV Infection and Hepatic Enzyme Abnormalities: Intricacies of the Pathogenic Mechanisms.; citation_author=S Pol; citation_author=P Lebray; citation_author=A Vallet-Pichard; citation_journal_title=Clinical Infectious Diseases; citation_volume=38; citation_number=22; citation_pages=65-72; citation_date=2004; " />
      <meta name="citation_reference" content="citation_title=Hepatotoxicity with antituberculosis drugs: the risk factors.; citation_author=K Mahmood; citation_author=A Hussain; citation_author=KL Jairamani; citation_author=A Talib; citation_author=B Abbasi; citation_journal_title=Pak J Med Sci; citation_volume=23; citation_number=23; citation_pages=33-38; citation_date=2007; " />
      <meta name="citation_reference" content="citation_title=HIV Medicine 2006. 2006: p. 395–480; citation_author=C Hoffmann; citation_author=JK Rockstroh; citation_author=BS Kamps; citation_number=24; " />
      <meta name="citation_reference" content="citation_title=antiretroviral therapy for HIV infection in adults and adolescents: Recommendations for a public health approach.; citation_number=25; citation_date=2006; " />
      <meta name="citation_reference" content="citation_title=Evaluation of risk factors for antituberculosis drugs-induced hepatotoxicity in Nepalese population.; citation_author=R Shakya; citation_author=BS Rao; citation_author=B Shrestha; citation_journal_title=Kathmandu university journal of science, engineering and technology; citation_volume=II; citation_number=26; citation_pages=1-8; citation_date=2006; " />
      <meta name="citation_reference" content="citation_title=Risk Factors of Hepatotoxicity During Anti-tuberculosis Treatment.; citation_author=A Anand; citation_author=AK Seth; citation_author=M Paul; citation_journal_title=MJAFI; citation_volume=62; citation_number=27; citation_pages=45-49; citation_date=2006; " />
      <meta name="citation_reference" content="citation_title=Occurrence of side effects from anti-tuberculosis drugs in urban Nepalese population under dots treatment.; citation_author=D Koju; citation_author=BS Rao; citation_author=B Shrestha; citation_author=R Shakya; citation_author=R Makaju; citation_journal_title=Kathmandu university journal of science, engineering and technology; citation_volume=1(1); citation_number=28; citation_date=2005; " />
      <meta name="citation_reference" content="citation_title=Xenobiotic-induced hepatotoxicity: mechanisms of liver injury and methods of monitoring hepatic function.; citation_author=MG Sturgill; citation_author=GH Lambert; citation_journal_title=Clin Chem; citation_volume=430; citation_number=29; citation_pages=1512-1526; citation_date=1997; " />
      <meta name="citation_reference" content="citation_title=Effect of anti-tuberculosis therapy on liver function of pulmonary tuberculosis patients infected with hepatitis B virus.; citation_author=L Pan; citation_author=Z Jia; citation_author=L Chen; citation_author=E Fu; citation_author=G Li; citation_journal_title=World J Gastroenterol; citation_volume=11; citation_number=30; citation_pages=2518-2521; citation_date=2005; " />
      <meta name="citation_reference" content="citation_title=Inactive Hepatitis B Surface Antigen Carrier State and Hepatotoxicity During Antituberculosis Chemotherapy.; citation_author=BH Lee; citation_author=W Koh; citation_author=MS Choi; citation_author=GY Suh; citation_author=MP Chung; citation_journal_title=Chest; citation_volume=127; citation_number=31; citation_pages=1304-1311; citation_date=2005; " />

  <link rel="canonical" href="http://www.plosone.org/article/info%3Adoi%2F10.1371%2Fjournal.pone.0001809" />

    <meta name="twitter:card" content="summary"/>
    <meta name="twitter:site" content="@plosone"/>
    <meta name="twitter:title" content="Anti-Tuberculosis Therapy-Induced Hepatotoxicity among Ethiopian HIV-Positive and Negative Patients"/>
    <meta name="twitter:description" content="BackgroundTo assess and compare the prevalence, severity and prognosis of anti-TB drug induced hepatotoxicity (DIH) in HIV positive and HIV negative tuberculosis (TB) patients in Ethiopia.Methodology/Principal FindingsIn this study, 103 HIV positive and 94 HIV negative TB patients were enrolled. All patients were evaluated for different risk factors and monitored biochemically and clinically for development of DIH. Sub-clinical hepatotoxicity was observed in 17.3% of the patients and 8 out of the 197 (4.1%) developed clinical hepatotoxicity. Seven of the 8 were HIV positive and 2 were positive for HBsAg.Conclusions/SignificanceSub-clinical hepatotoxicity was significantly associated with HIV co-infection (p&#8202;=&#8202;0.002), concomitant drug intake (p&#8202;=&#8202;0.008), and decrease in CD4 count (p&#8202;=&#8202;0.001). Stepwise restarting of anti TB treatment was also successful in almost all the patients who developed clinical DIH. We therefore conclude that anti-TB DIH is a major problem in HIV-associated TB with a decline in immune status and that there is a need for a regular biochemical and clinical follow up for those patients who are at risk."/>
      <meta name="twitter:image" content="http://dx.plos.org/10.1371/journal.pone.0001809.t004"/>

  <meta property="og:title" content="Anti-Tuberculosis Therapy-Induced Hepatotoxicity among Ethiopian HIV-Positive and Negative Patients" />
  <meta property="og:type" content="article" />
  <meta property="og:url" content="http://www.plosone.org/article/info%3Adoi%2F10.1371%2Fjournal.pone.0001809" />

 <!--end articleInfoX-->

  <link rel="pingback" href="http://www.plosone.org/pingback" />


  <link rel="shortcut icon" href="/images/favicon.ico" type="image/x-icon"/>
  <link rel="home" title="home" href="/"/>
  <link rel="alternate" type="application/rss+xml"
        title="PLOS ONE: New Articles"
        href="http://www.plosone.org/article/feed"/>
</head>
<body>

  <div id="page-wrap">
    <div id="topbanner" class="cf">

<!-- Div for the ad at the top of journal home page-->
<div class="center">
  <div class="title">Advertisement</div>
  <iframe id='a3ac9da4' name='a3ac9da4'
    src='http://ads.plos.org/www/delivery/afr.php?zoneid=345&amp;cb=3542'
    frameborder='0' scrolling='no' width='730' height='90'>
    <a href='http://ads.plos.org/www/delivery/ck.php?n=a3ac9da4&amp;cb=5362'
      target='_top'><img src='http://ads.plos.org/www/delivery/avw.php?zoneid=345&amp;cb=4386&amp;n=a3ac9da4'
      border='0' alt=''/>
    </a>
  </iframe>
</div>    </div>

    <div id="pagehdr-wrap">
      <div id="pagehdr">
        <div id="user" class="nav">
          <ul>
            <li><a href="http://www.plos.org">plos.org</a></li>
            <li><a href="https://register.plos.org/ambra-registration/register.action">create account</a></li>
            <li class="btn-style"><a
              href="/user/secure/secureRedirect.action?goTo=%2Farticle%2FfetchArticle.action%3FarticleURI%3Dinfo%253Adoi%252F10.1371%252Fjournal.pone.0001809">sign in</a>
            </li>
          </ul>
        </div>
        <div class="logo">
          <a href="/"><img src="/images/logo.png" alt="PLOS ONE"></a>
        </div>

<div id="nav-main" class="nav">
  <ul>
        <li id="mn-01"><a href="/taxonomy" class="areas-link">Subject Areas</a></li>
    <li id="mn-02"><a href="javascript:void(0);">For Authors</a>
      <div class="submenu" style="width: 540px; margin-left: -300px;">
        <div class="block">
          <div class="submit-script">
            <h3>Submit your Manuscript</h3>
            <ul>
              <li>Fair, rigorous peer review</li>
              <li>Broad scope and wide reach</li>
            </ul>
            <a href="/static/submissionInstructions" class="btn">get started</a>
          </div>
        </div>
        <div class="menu">
          <ul>
            <li><a href="/static/publish">Why Publish with PLOS ONE</a></li>
            <li><a href="/static/publication">Publication Criteria</a></li>
            <li><a href="/static/editorial">Editorial Policies</a></li>
            <li><a href="/static/guidelines">Preparing A Manuscript</a></li>
            <li><a href="/static/figureGuidelines">Figure and Table Guidelines</a></li>
          <li><a href="/static/supportingInformation">Supporting Information Guidelines</a></li>
            <li><a href="/static/submissionInstructions">Submitting a Manuscript</a></li>
          </ul>
        </div>
      </div>
    </li>

    <li id="mn-03"><a href="javascript:void(0);">About Us</a>
      <div class="submenu" style="width:248px; margin-left:-30px;">
        <div class="menu">
          <ul>
            <li><a href="/static/information">Journal Information</a></li>
            <li><a href="/static/edboard">Editorial Board</a></li>
            <li><a href="/static/reviewerGuidelines">Reviewer Guidelines</a></li>
            <li><a href="/static/almInfo">Article-Level Metrics</a></li>
            <li><a href="/static/license">Open-Access License</a></li>
            <li><a href="/static/downloads">Media Downloads</a></li>
            <li><a href="/static/commentGuidelines">Guidelines for Comments</a></li>
            <li><a href="/static/corrections">Corrections</a></li>
            <li><a href="/static/help">Help Using this Site</a></li>
            <li><a href="/static/contact">Contact Us</a></li>
          </ul>
        </div>
      </div>
    </li>
  </ul>
<div id="db">
  <form name="searchForm" action="/search/simple?noSearchFlag=true&amp;query=&amp;articleURI=info%3Adoi%2F10.1371%2Fjournal.pone.0001809" method="get" >
<input type="hidden" name="from" value="globalSimpleSearch" id="from"/><input type="hidden" name="filterJournals" value="PLoSONE" id="filterJournals"/>    <fieldset>
      <legend>Search</legend>
      <label for="search">Search</label>
      <div class="wrap">
        <input id="search" type="text" name="query" placeholder="Search">
        <input type="image" alt="SEARCH" src="/images/icon.search.gif">
      </div>
    </fieldset>
  </form>
    <a id="advSearch" href="/search/advanced?noSearchFlag=true&amp;query=&amp;articleURI=info%3Adoi%2F10.1371%2Fjournal.pone.0001809&filterJournals=PLoSONE">advanced search</a>
</div></div>

      </div>
      <!-- pagehdr-->
    </div>
    <!-- pagehdr-wrap -->

  <!--body and html tags gets closed in global_footer.ftl-->
<script type="text/javascript" src="/javascript/mathjax/MathJax.js?config=TeX-AMS-MML_HTMLorMML"></script>

<div id="pagebdy-wrap">
  <div id="pagebdy">

    <div id="article-block" class="cf">

<div class="article-meta cf">
  <ul id="almSignPost" style="display: none;"></ul>
  <div class="article-type">
    <span class="type oa">Open Access</span>
      <span class="type pr">Peer-Reviewed</span>
  </div>
</div>

<div class="header" id="hdr-article">

<div class="article-kicker">
      <span id="article-type-heading">
        Research Article
      </span>
</div>  <h1 property="dc:title" datatype="" rel="dc:type" href="http://purl.org/dc/dcmitype/Text">
    Anti-Tuberculosis Therapy-Induced Hepatotoxicity among Ethiopian HIV-Positive and Negative Patients
  </h1>

  <ul class="authors">
      <li>


        <span rel="dc:creator" class="author">
          <span class="person" property="foaf:name" typeof="foaf:Person">
            Getnet Yimer, 
          </span>
        </span>

          <div class="author_meta">
            <div class="author_inner">


              
              

                <p>Affiliations:
                  Armauer Hansen Research Institute, Addis Ababa, Ethiopia, 
                  Addis Ababa University, Medical Faculty, Addis Ababa, Ethiopia
                </p>


              <span class="close">X</span>

            </div>
          </div>
      </li>
      <li>


        <span rel="dc:creator" class="author">
          <span class="person" property="foaf:name" typeof="foaf:Person">
            Getachew Aderaye
              <span class="corresponding">mail</span>, 
          </span>
        </span>

          <div class="author_meta">
            <div class="author_inner">


              
              <p><span class="email">* E-mail:</span> <a href="mailto:getadera@yahoo.com">getadera@yahoo.com</a></p>

                <p>Affiliation:
                  Addis Ababa University, Medical Faculty, Addis Ababa, Ethiopia
                </p>


              <span class="close">X</span>

            </div>
          </div>
      </li>
      <li>


        <span rel="dc:creator" class="author">
          <span class="person" property="foaf:name" typeof="foaf:Person">
            Wondwossen Amogne, 
          </span>
        </span>

          <div class="author_meta">
            <div class="author_inner">


              
              

                <p>Affiliation:
                  Addis Ababa University, Medical Faculty, Addis Ababa, Ethiopia
                </p>


              <span class="close">X</span>

            </div>
          </div>
      </li>
      <li>


        <span rel="dc:creator" class="author">
          <span class="person" property="foaf:name" typeof="foaf:Person">
            Eyasu Makonnen, 
          </span>
        </span>

          <div class="author_meta">
            <div class="author_inner">


              
              

                <p>Affiliation:
                  Addis Ababa University, Medical Faculty, Addis Ababa, Ethiopia
                </p>


              <span class="close">X</span>

            </div>
          </div>
      </li>
      <li>


        <span rel="dc:creator" class="author">
          <span class="person" property="foaf:name" typeof="foaf:Person">
            Eleni Aklillu, 
          </span>
        </span>

          <div class="author_meta">
            <div class="author_inner">


              
              

                <p>Affiliation:
                  Department of Clinical Pharmacology, Karolinska Institute, Stockholm, Sweden
                </p>


              <span class="close">X</span>

            </div>
          </div>
      </li>
      <li>


        <span rel="dc:creator" class="author">
          <span class="person" property="foaf:name" typeof="foaf:Person">
            Lars Lindquist, 
          </span>
        </span>

          <div class="author_meta">
            <div class="author_inner">


              
              

                <p>Affiliation:
                  Department of Internal Medicine, Infectious Disease Unit, Karolinska Institute, Stockholm, Sweden
                </p>


              <span class="close">X</span>

            </div>
          </div>
      </li>
      <li>


        <span rel="dc:creator" class="author">
          <span class="person" property="foaf:name" typeof="foaf:Person">
            Lawrence Yamuah, 
          </span>
        </span>

          <div class="author_meta">
            <div class="author_inner">


              
              

                <p>Affiliation:
                  Armauer Hansen Research Institute, Addis Ababa, Ethiopia
                </p>


              <span class="close">X</span>

            </div>
          </div>
      </li>
      <li>


        <span rel="dc:creator" class="author">
          <span class="person" property="foaf:name" typeof="foaf:Person">
            Beniyam Feleke, 
          </span>
        </span>

          <div class="author_meta">
            <div class="author_inner">


              
              

                <p>Affiliation:
                  St. Peter's TB Specialized Hospital, Addis Ababa, Ethiopia
                </p>


              <span class="close">X</span>

            </div>
          </div>
      </li>
      <li>


        <span rel="dc:creator" class="author">
          <span class="person" property="foaf:name" typeof="foaf:Person">
            Abraham Aseffa
          </span>
        </span>

          <div class="author_meta">
            <div class="author_inner">


              
              

                <p>Affiliation:
                  Armauer Hansen Research Institute, Addis Ababa, Ethiopia
                </p>


              <span class="close">X</span>

            </div>
          </div>
      </li>
  </ul>
  <ul class="date-doi-line">
    <li>Published: March 19, 2008</li>
    <li>DOI: 10.1371/journal.pone.0001809</li>
  </ul>


</div><!--end header-->
<div class="main cf" id="pjax-container">
  

<div class="nav items-5" id="nav-article">
  <ul>
  <li>
        <span class="active" name="article">Article</span>
  </li>
  <li>
      <a href="/article/authors/info%3Adoi%2F10.1371%2Fjournal.pone.0001809" name="authors">About the Authors</a>
  </li>
  <li>
      <a href="/article/metrics/info%3Adoi%2F10.1371%2Fjournal.pone.0001809" name="metrics">Metrics</a>
  </li>
  <li>
      <a href="/article/comments/info%3Adoi%2F10.1371%2Fjournal.pone.0001809" name="comments">Comments</a>
  </li>
  <li>
      <a href="/article/related/info%3Adoi%2F10.1371%2Fjournal.pone.0001809" name="related">Related Content</a>
  </li>
  </ul>
</div>

<script type="text/javascript">
  var selected_tab = "article";
</script>
  <div id="figure-thmbs" class="carousel cf">
    <div class="wrapper">
      <div class="slider">
              <div class="item">
                <a href="#pone-0001809-t001" data-doi="info:doi/10.1371/journal.pone.0001809" data-uri="info:doi/10.1371/journal.pone.0001809.t001" title="Table 1">
                  <span class="thmb-wrap">
                    <img src="/article/fetchObject.action?uri=info:doi/10.1371/journal.pone.0001809.t001&representation=PNG_I" alt="">
                  </span>
                </a>
              </div>
              <div class="item">
                <a href="#pone-0001809-t002" data-doi="info:doi/10.1371/journal.pone.0001809" data-uri="info:doi/10.1371/journal.pone.0001809.t002" title="Table 2">
                  <span class="thmb-wrap">
                    <img src="/article/fetchObject.action?uri=info:doi/10.1371/journal.pone.0001809.t002&representation=PNG_I" alt="">
                  </span>
                </a>
              </div>
              <div class="item">
                <a href="#pone-0001809-t003" data-doi="info:doi/10.1371/journal.pone.0001809" data-uri="info:doi/10.1371/journal.pone.0001809.t003" title="Table 3">
                  <span class="thmb-wrap">
                    <img src="/article/fetchObject.action?uri=info:doi/10.1371/journal.pone.0001809.t003&representation=PNG_I" alt="">
                  </span>
                </a>
              </div>
              <div class="item">
                <a href="#pone-0001809-t004" data-doi="info:doi/10.1371/journal.pone.0001809" data-uri="info:doi/10.1371/journal.pone.0001809.t004" title="Table 4">
                  <span class="thmb-wrap">
                    <img src="/article/fetchObject.action?uri=info:doi/10.1371/journal.pone.0001809.t004&representation=PNG_I" alt="">
                  </span>
                </a>
              </div>
      </div>
    </div>
  </div>

  <div class="nav-col">
    <div class="nav" id="nav-article-page">
      <ul>
        <li class="nav-col-comments"><a href="/article/comments/info%3Adoi%2F10.1371%2Fjournal.pone.0001809">Reader Comments (0)</a></li>
          <li id="nav-figures"><a data-doi="info:doi/10.1371/journal.pone.0001809" >Figures</a></li>
      </ul>
    </div>
  </div>

  <div class="article">







<div class="abstract"><a id="abstract0" name="abstract0" toc="abstract0" title="Abstract"></a><h2>Abstract</h2>
<h3>Background</h3>
<a id="article1.front1.article-meta1.abstract1.sec1.p1" name="article1.front1.article-meta1.abstract1.sec1.p1"></a><p>To assess and compare the prevalence, severity and prognosis of anti-TB drug induced hepatotoxicity (DIH) in HIV positive and HIV negative tuberculosis (TB) patients in Ethiopia.</p>


<h3>Methodology/Principal Findings</h3>
<a id="article1.front1.article-meta1.abstract1.sec2.p1" name="article1.front1.article-meta1.abstract1.sec2.p1"></a><p>In this study, 103 HIV positive and 94 HIV negative TB patients were enrolled. All patients were evaluated for different risk factors and monitored biochemically and clinically for development of DIH. Sub-clinical hepatotoxicity was observed in 17.3% of the patients and 8 out of the 197 (4.1%) developed clinical hepatotoxicity. Seven of the 8 were HIV positive and 2 were positive for HBsAg.</p>


<h3>Conclusions/Significance</h3>
<a id="article1.front1.article-meta1.abstract1.sec3.p1" name="article1.front1.article-meta1.abstract1.sec3.p1"></a><p>Sub-clinical hepatotoxicity was significantly associated with HIV co-infection (p = 0.002), concomitant drug intake (p = 0.008), and decrease in CD4 count (p = 0.001). Stepwise restarting of anti TB treatment was also successful in almost all the patients who developed clinical DIH. We therefore conclude that anti-TB DIH is a major problem in HIV-associated TB with a decline in immune status and that there is a need for a regular biochemical and clinical follow up for those patients who are at risk.</p>

</div>


<div class="articleinfo"><p><strong>Citation: </strong>Yimer G, Aderaye G, Amogne W, Makonnen E, Aklillu E, et al.  (2008) Anti-Tuberculosis Therapy-Induced Hepatotoxicity among Ethiopian HIV-Positive and Negative Patients. PLoS ONE 3(3):
          e1809.
            doi:10.1371/journal.pone.0001809</p><p><strong>Academic Editor: </strong>Landon Myer, University of Cape Town, South Africa</p><p><strong>Received:</strong> May 24, 2007; <strong>Accepted:</strong> February 17, 2008; <strong>Published:</strong> March 19, 2008</p><p><strong>Copyright:</strong> © 2008 Yimer et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.</p><p><strong>Funding: </strong>The study done in Ethiopia was fully funded by AHRI, with part of the study done in Sweden funded by Sida/SAREC grant HIV-2006-031.</p><p><strong>Competing interests:</strong> The authors have declared that no competing interests exist.</p></div>





<div id="section1" class="section"><a id="s1" name="s1" toc="s1" title="Introduction"></a><h3>Introduction</h3><a id="article1.body1.sec1.p1" name="article1.body1.sec1.p1"></a><p>The magnitude of tuberculosis (TB) has increased globally since 1990 due to spread of human immunodeficiency virus (HIV) and population growth<a href="#pone.0001809-Dye1">[1]</a>. It is estimated that <em>Mycobacterium tuberculosis</em> has infected one-third of the world's population and 8–9 million new TB cases occur each year. <a href="#pone.0001809-Yepes1">[2]</a>–<a href="#pone.0001809-Focusdisease1">[7]</a> In populations with high HIV prevalence, TB is the leading cause of morbidity and mortality. <a href="#pone.0001809-Aaron1">[4]</a>, <a href="#pone.0001809-Gooze1">[6]</a>, <a href="#pone.0001809-WHO1">[8]</a></p>
<a id="article1.body1.sec1.p2" name="article1.body1.sec1.p2"></a><p>Hepatotoxicity is one of the most important adverse drug reactions associated with anti-tuberculosis drugs that may limit their use.<a href="#pone.0001809-Bassey1">[5]</a> Previous studies showed transient elevations of serum hepatocellular enzymes (e.g. alanine aminotransferase and aspartate aminotransferase) in approximately 10% of patients who received a standard combination chemotherapy including isoniazid and rifampicin, of these 1–2% patients withdrew from the treatment because of severe hepatotoxicity that ultimately led to fulminant hepatitis. <a href="#pone.0001809-Ali1">[9]</a></p>
<a id="article1.body1.sec1.p3" name="article1.body1.sec1.p3"></a><p>Although the occurrence of drug induced hepatotoxicity (DIH) is difficult to predict, it has been observed that certain patients are at higher risk during the course of anti-TB chemotherapy <a href="#pone.0001809-Cheukming1">[10]</a>–<a href="#pone.0001809-CamposFranco1">[17]</a>. Various studies have suggested that high alcohol intake, older age, slow acetylation status, pre-existing chronic liver disease, chronic viral infection due to hepatitis B and hepatitis C, HIV infection, advanced tuberculosis, Asian ethnicity, female sex, concomitant administration of enzyme-inducers (e.g. barbiturates and anaesthetic agents), inappropriate use of drugs and poor nutritional status increase the risk of anti-tuberculosis drug induced hepatitis. <a href="#pone.0001809-Cheukming1">[10]</a>–<a href="#pone.0001809-CamposFranco1">[17]</a></p>
<a id="article1.body1.sec1.p4" name="article1.body1.sec1.p4"></a><p>It has been suggested that AIDS is significantly associated with development of hepatotoxicity.<a href="#pone.0001809-Ozick1">[18]</a> However, the reason for this association is currently unknown, but may reflect disease-induced alterations in bioactivation or detoxification of reactive metabolites, as well as immunedysregulation. <a href="#pone.0001809-Gross1">[19]</a> Besides, there has not been any study that showed the association between CD4 count and development of hepatotoxicity among the HIV infected patients. <a href="#pone.0001809-Ali1">[9]</a></p>
<a id="article1.body1.sec1.p5" name="article1.body1.sec1.p5"></a><p>In this study, we aimed at determining the possible risk factors for development of DIH in both HIV-infected (none of which received ART) and non-infected TB patients from Ethiopia.</p>
</div>

<div id="section2" class="section"><a id="s2" name="s2" toc="s2" title="Materials and Methods"></a><h3>Materials and Methods</h3><a id="article1.body1.sec2.p1" name="article1.body1.sec2.p1"></a><p>In this cohort study Ethiopian TB patients were followed and gave rise to a group of cases of hepatotoxicity and controls (no hepatotoxicity). The study was conducted from August 2004 to March 2005, 103 HIV positive and 94 HIV negative consecutive newly diagnosed male and female adult patients were prospectively evaluated.</p>
<a id="article1.body1.sec2.p2" name="article1.body1.sec2.p2"></a><p>Diagnosis of tuberculosis was based on sputum smear, fine needle aspirate (FNA), and clinical and radiological evidence. The criteria for diagnosis was based on the Ethiopian National guideline for diagnosis of tuberculosis.<sup>21</sup> The number of patients who had smear positive TB were 99, smear negative 39, extra-pulmonary 32, and disseminated 17. Patients were excluded if they had a history of prior treatment for tuberculosis, did not consent for HIV testing, were less than 18 years of age and had clinical evidence of liver damage prior to starting medication. Patients were put on DOTS and regimens with rifampicin, isoniazid, and pyrazinamide (44 patients) or rifampicin, isoniazid, pyrazinamide and either ethambutol (10 patients) or streptomycin (142 patients) were given for 2 months of intensive phase (<a href="#pone-0001809-t001">table 1</a>). During the 6 months of continuation phase all patients were put on rifampicin plus ethambutol.</p>
<div class="figure" id="pone-0001809-t001"><div class="img"><a name="pone-0001809-t001" title="Click for larger image " href="/article/fetchObject.action?uri=info:doi/10.1371/journal.pone.0001809.t001&amp;representation=PNG_M" data-doi="info:doi/10.1371/journal.pone.0001809" data-uri="info:doi/10.1371/journal.pone.0001809.t001"><img src="/article/fetchObject.action?uri=info:doi/10.1371/journal.pone.0001809.t001&amp;representation=PNG_I" alt="thumbnail" class="thumbnail"></a></div><div class="figure-inline-download">
            Download:
            <ul><li><div class="icon"><a href="/article/info:doi/10.1371/journal.pone.0001809.t001/powerpoint">
                    PPT
                  </a></div><a href="/article/info:doi/10.1371/journal.pone.0001809.t001/powerpoint">
                  PowerPoint slide
                </a></li><li><div class="icon"><a href="/article/info:doi/10.1371/journal.pone.0001809.t001/largerimage">
                    PNG
                  </a></div><a href="/article/info:doi/10.1371/journal.pone.0001809.t001/largerimage">
                  larger image
                  (<span id="info:doi/10.1371/journal.pone.0001809.t001.PNG_L"></span>)
                </a></li><li><div class="icon"><a href="/article/info:doi/10.1371/journal.pone.0001809.t001/originalimage">
                    TIFF
                  </a></div><a href="/article/info:doi/10.1371/journal.pone.0001809.t001/originalimage">
                  original image
                  (<span id="info:doi/10.1371/journal.pone.0001809.t001.TIF"></span>)
                </a></li></ul></div><p><strong>Table 1.  <span>Risk factors for development of sub-clinical and clinical hepatotoxicity, Addis Ababa, Ethiopia, August 2004-March 2005</span></strong></p><span>doi:10.1371/journal.pone.0001809.t001</span></div><a id="article1.body1.sec2.p3" name="article1.body1.sec2.p3"></a><p>For all the patients involved in the study a complete history and physical examination were taken. Laboratory tests done before initiation of anti-TB drugs included; complete and differential blood counts, erythrocyte sedimentation rate (ESR), liver function tests including aspartate aminotransferase (AST), alanine aminotransferase (ALT), direct and total bilurubin and alkaline phosphatase, serological tests for hepatitis B surface antigen (HBsAg) and anti-hepatitis C antibody (anti-HCV). Liver function tests were performed before initiation of anti-TB drugs and late at 1, 2, 4, 6 and 8 weeks after starting DOTS.</p>
<a id="article1.body1.sec2.p4" name="article1.body1.sec2.p4"></a><p>Diagnosis of HIV was made based on the National HIV diagnosis algorithm using rapid test kits (Determine, Capillus and Unigold). CD4 count was done for HIV positive patients following the procedure of Flow cytometer after staining the cells within the first week of enrolling participants. FACS COUNT, BECTON DICKINSON, USA is used for counting the CD4 cells.</p>

<h4>Sampling</h4>
<a id="article1.body1.sec2.sec1.p1" name="article1.body1.sec2.sec1.p1"></a><p>To answer the question that HIV infection is a risk factor for development of hepatotoxicity in patients taking anti-tuberculosis therapy we set the level of significance and the power of the study at 5% and 80% respectively. A 2.5% and 25% prevalence of anti-TB DIH in HIV negative and HIV positive patients respectively was considered in determining the sample size. The ratio between patients with TB alone and TB/HIV co-infection was taken as 1:1. Accordingly the required sample size to detect a minimal difference in proportion of patients with hepatotoxicity between the HIV positives and HIV negatives TB patients was 67 per group.</p>


<h4>Diagnosis of anti-tuberculosis DIH (Adopted from the Council for International Organizations of Medical Sciences (CIOMS) scale)</h4>
<h5>1. Biochemical DIH (Sub-Clinical hepatotoxicity).</h5><a id="article1.body1.sec2.sec2.sec1.p1" name="article1.body1.sec2.sec2.sec1.p1"></a><p>Patients were diagnosed to have biochemical hepatotoxicity if there was no apparent cause for the raised liver function tests plus if he/she had one of the following: a rise of five times the upper limit of normal levels (31 U/L) of serum alanine aminotransferase (ALT) and no sign and symptom of DIH.</p>

<h5>2. Clinical DIH.</h5><a id="article1.body1.sec2.sec2.sec2.p1" name="article1.body1.sec2.sec2.sec2.p1"></a><p>Clinical hepatotoxicity was diagnosed if a patient had biochemical hepatotoxicity plus symptoms of DIH including: nausea, vomiting, weakness and jaundice.</p>



<h4>Desensitization protocol for patients who developed clinical DIH</h4>
<a id="article1.body1.sec2.sec3.p1" name="article1.body1.sec2.sec3.p1"></a><p>After discontinuing all the anti-tuberculosis therapy, patients were followed by both clinically and biochemical parameters for signs and symptoms of DIH. By the time when all the signs and symptoms of DIH disappeared and the liver function tests dropped down to the normal range, patients were reinitiated on their anti-tuberculosis therapy based on the following protocol. Isoniazid 50 mg per day, followed by isoniazid 100 mg per day, followed by isoniazid 200 mg and rifampicin 300 mg per day, followed by RHZ 1tab and RH 2 tabs per day, followed by RHZ 2 tabs and RH 1 tab per day, followed by RHZE 3 tabs per day, and finally the normal dose for the patient based on the patients weight. Desensitization was done every three days and the dosages of rifampicin and isoniazid in RH were 150 mg and 75 mg, rifampicin, isoniazid and pyrazinamide in RHZ were 150 mg, 75 mg, and 400 mg and that of rifampicin, isoniazid, pyrazinamide and ethambutol in the RHZE were 150 mg, 75 mg, 400 mg, and 275 mg respectively. The intensive phase was also prolonged by considering as if the patient was not on treatment during the discontinuation and desensitization period. This desensitization protocol was adopted from the normal hospital practice for management of DIH in the study site.</p>


<h4>Ethical consideration</h4>
<a id="article1.body1.sec2.sec4.p1" name="article1.body1.sec2.sec4.p1"></a><p>The study protocol was approved by two institutional IRBs and one National Ethical Review Committee which gives the final decision at the national level. Therefore, ethical approval was obtained from: IRB of Armauer Hansen research Institute, FRPC (Faculty research and publication committee) of Faculty Medicine Addis Ababa University, and the National Health Science and Technology Council and Ethics Review Committee. Written informed consent for HIV testing and participation in the study was obtained from all participants prior to the commencement of the study. Opportunistic infections were treated free of charge. HIV positive patients were eventually linked to HIV patients care and support center. Due to the unavailability of antiretroviral drugs nationally at the time of the study patients were not provided ART.</p>


<h4>Statistical analysis</h4>
<a id="article1.body1.sec2.sec5.p1" name="article1.body1.sec2.sec5.p1"></a><p>Data were double entered and checked. HIV positive and negative TB patients were compared and SPSS version 11.0 was used for analysis of the different risk factors for development of Hepatotoxicity. Chi-square, Fishers exact tests and multivariate analysis were used to test for the level of significance. Multiple regression analysis was used to see the effect of different confounding factors. Clinical and biochemical hepatotoxicity were the dependant variables whereas age, sex, HBsAg, concomitant drug intake, HIV status, body mass index, CD4 count and anti-HCV antibody were the independent variables. OR and P-values are used to see the significant risk factors. Variables with p&lt;0.05 were considered potential predictors of DIH.</p>

</div>

<div id="section3" class="section"><a id="s3" name="s3" toc="s3" title="Results"></a><h3>Results</h3>
<h4>Patients</h4>
<a id="article1.body1.sec3.sec1.p1" name="article1.body1.sec3.sec1.p1"></a><p>Out of the 197 study participants 105 (52.8%) were male and 92 (47.2%) were female; the median age of the patients was 26 years (range, 18 to 67 years). Out of these patients, 103 (52.3%) patients were HIV positive and 94 (47.7%) patients were negative. CD4 count was done for 87 of the 103 HIV positive patients and the distribution is shown in <a href="#pone-0001809-t001">Table 1</a>. Eighty percent of the patients had CD4 count less than 200 cells/mm<sup>3</sup>.Fourteen (7.2%) were positive for HBsAg and only 4 (2.2 %) were positive for anti-HCV.</p>
<a id="article1.body1.sec3.sec1.p2" name="article1.body1.sec3.sec1.p2"></a><p>Among the 195 patients 146 (74.9%) had pulmonary tuberculosis of whom 107 (73.3%) had smear positive and 39 (26.7%) had smear negative TB. Thirty two (16.4%) of the patients had extra pulmonary TB and 17 (8.7%) had disseminated TB (<a href="#pone-0001809-t002">Table 2</a>).</p>
<div class="figure" id="pone-0001809-t002"><div class="img"><a name="pone-0001809-t002" title="Click for larger image " href="/article/fetchObject.action?uri=info:doi/10.1371/journal.pone.0001809.t002&amp;representation=PNG_M" data-doi="info:doi/10.1371/journal.pone.0001809" data-uri="info:doi/10.1371/journal.pone.0001809.t002"><img src="/article/fetchObject.action?uri=info:doi/10.1371/journal.pone.0001809.t002&amp;representation=PNG_I" alt="thumbnail" class="thumbnail"></a></div><div class="figure-inline-download">
            Download:
            <ul><li><div class="icon"><a href="/article/info:doi/10.1371/journal.pone.0001809.t002/powerpoint">
                    PPT
                  </a></div><a href="/article/info:doi/10.1371/journal.pone.0001809.t002/powerpoint">
                  PowerPoint slide
                </a></li><li><div class="icon"><a href="/article/info:doi/10.1371/journal.pone.0001809.t002/largerimage">
                    PNG
                  </a></div><a href="/article/info:doi/10.1371/journal.pone.0001809.t002/largerimage">
                  larger image
                  (<span id="info:doi/10.1371/journal.pone.0001809.t002.PNG_L"></span>)
                </a></li><li><div class="icon"><a href="/article/info:doi/10.1371/journal.pone.0001809.t002/originalimage">
                    TIFF
                  </a></div><a href="/article/info:doi/10.1371/journal.pone.0001809.t002/originalimage">
                  original image
                  (<span id="info:doi/10.1371/journal.pone.0001809.t002.TIF"></span>)
                </a></li></ul></div><p><strong>Table 2.  <span>Frequency distribution of demographic and clinical variables, Addis Ababa, Ethiopia, August 2004-March 2005</span></strong></p><span>doi:10.1371/journal.pone.0001809.t002</span></div><a id="article1.body1.sec3.sec1.p3" name="article1.body1.sec3.sec1.p3"></a><p>Only 55 (27.9%) patients from the 197 took other drugs concomitantly and these drugs were: Vitamin B<sub>6</sub> (7 patients), codeine phosphate (5 patients), promethazine (4 patients) amoxicillin (13 patients), antiacid syrup (13), albendazole (3 patients), tetracycline (2 patients), phenobarbitone (2 patients), ampicillin and gentamincine (2 patients), phenobarbitone plus antiacid syrup (1 patient), ketoconazole (1 patient), and trimethoprim/sulfamethoxazole (2 patients).</p>
<a id="article1.body1.sec3.sec1.p4" name="article1.body1.sec3.sec1.p4"></a><p>The Body Mass Index (BMI) of the HIV positive patients was &lt;18.5 for 61 (59.2%) whereas BMI for the HIV negative patients was &lt;18.5 for 47 (50.0%) and the differences were not significant between the 2 groups of patients (p&gt;0.05)(<a href="#pone-0001809-t002">Table 2</a>). However, comparison of BMI in patients with and with out DIH was not done as the number of patients with DIH is very small.</p>


<h4>Association of sub-clinical hepatotoxicity with demographic and clinical variables</h4>
<a id="article1.body1.sec3.sec2.p1" name="article1.body1.sec3.sec2.p1"></a><p>Thirty four (17.3%) study participants had sub-clinical hepatotoxicity of which 8 (4.1%) developed clinical hepatotoxicity with all of them having jaundice and necessitated discontinuation of their anti-tuberculosis therapy. Out of the 34 patients 14 (41.2%) were males and 20 (58.8%) were females. Twenty six (76.5%) were HIV positive and 8 (23.5%) were negative. Twenty two (66.7%) patients were &lt;35 years of age and the mean time for the development of sub-clinical DIH was 2.8 weeks (Range 1–8 weeks). The mean duration of stay of the elevated ALT was 2.2 weeks (Range 1–7 weeks).</p>
<a id="article1.body1.sec3.sec2.p2" name="article1.body1.sec3.sec2.p2"></a><p>Multivariate and bivariate analyses were performed to see the association between different variables and development of clinical and biochemical hepatotoxicity. The effect of confounders such as age, sex, HBsAg, concomitant drug intake, HIV status, body mass index, CD4 count and anti-HCV antibody was controlled. The results of the analyses showed that the odds of developing biochemical hepatotoxicity in patients taking other drugs concomitantly was 2.7 with a 95% CI of 1.2–5.8. The odds of developing biochemical hepatotoxicity in HIV positive patients was 3.6 with a 95% CI of 1.5–8.5 as compared to that of HIV negative patients (<a href="#pone-0001809-t001">Table 1</a>, <a href="#pone-0001809-t003">3</a> and <a href="#pone-0001809-t004">4</a>).</p>
<div class="figure" id="pone-0001809-t003"><div class="img"><a name="pone-0001809-t003" title="Click for larger image " href="/article/fetchObject.action?uri=info:doi/10.1371/journal.pone.0001809.t003&amp;representation=PNG_M" data-doi="info:doi/10.1371/journal.pone.0001809" data-uri="info:doi/10.1371/journal.pone.0001809.t003"><img src="/article/fetchObject.action?uri=info:doi/10.1371/journal.pone.0001809.t003&amp;representation=PNG_I" alt="thumbnail" class="thumbnail"></a></div><div class="figure-inline-download">
            Download:
            <ul><li><div class="icon"><a href="/article/info:doi/10.1371/journal.pone.0001809.t003/powerpoint">
                    PPT
                  </a></div><a href="/article/info:doi/10.1371/journal.pone.0001809.t003/powerpoint">
                  PowerPoint slide
                </a></li><li><div class="icon"><a href="/article/info:doi/10.1371/journal.pone.0001809.t003/largerimage">
                    PNG
                  </a></div><a href="/article/info:doi/10.1371/journal.pone.0001809.t003/largerimage">
                  larger image
                  (<span id="info:doi/10.1371/journal.pone.0001809.t003.PNG_L"></span>)
                </a></li><li><div class="icon"><a href="/article/info:doi/10.1371/journal.pone.0001809.t003/originalimage">
                    TIFF
                  </a></div><a href="/article/info:doi/10.1371/journal.pone.0001809.t003/originalimage">
                  original image
                  (<span id="info:doi/10.1371/journal.pone.0001809.t003.TIF"></span>)
                </a></li></ul></div><p><strong>Table 3.  <span>Unadjusted analyses of the association between sub-clinical hepatotoxicity with different demographic and clinical variables, Addis Ababa, August 2004-March 2005</span></strong></p><span>doi:10.1371/journal.pone.0001809.t003</span></div><div class="figure" id="pone-0001809-t004"><div class="img"><a name="pone-0001809-t004" title="Click for larger image " href="/article/fetchObject.action?uri=info:doi/10.1371/journal.pone.0001809.t004&amp;representation=PNG_M" data-doi="info:doi/10.1371/journal.pone.0001809" data-uri="info:doi/10.1371/journal.pone.0001809.t004"><img src="/article/fetchObject.action?uri=info:doi/10.1371/journal.pone.0001809.t004&amp;representation=PNG_I" alt="thumbnail" class="thumbnail"></a></div><div class="figure-inline-download">
            Download:
            <ul><li><div class="icon"><a href="/article/info:doi/10.1371/journal.pone.0001809.t004/powerpoint">
                    PPT
                  </a></div><a href="/article/info:doi/10.1371/journal.pone.0001809.t004/powerpoint">
                  PowerPoint slide
                </a></li><li><div class="icon"><a href="/article/info:doi/10.1371/journal.pone.0001809.t004/largerimage">
                    PNG
                  </a></div><a href="/article/info:doi/10.1371/journal.pone.0001809.t004/largerimage">
                  larger image
                  (<span id="info:doi/10.1371/journal.pone.0001809.t004.PNG_L"></span>)
                </a></li><li><div class="icon"><a href="/article/info:doi/10.1371/journal.pone.0001809.t004/originalimage">
                    TIFF
                  </a></div><a href="/article/info:doi/10.1371/journal.pone.0001809.t004/originalimage">
                  original image
                  (<span id="info:doi/10.1371/journal.pone.0001809.t004.TIF"></span>)
                </a></li></ul></div><p><strong>Table 4.  <span>Multivariate analyses of an association between sub-clinical hepatotoxicity with different clinical variables, Addis Ababa, August 2004–March 2005</span></strong></p><span>doi:10.1371/journal.pone.0001809.t004</span></div><a id="article1.body1.sec3.sec2.p3" name="article1.body1.sec3.sec2.p3"></a><p>Three (21.4%) of the HBsAg positive and 31 (17.1%) of the HBsAg negative study participants developed sub-clinical hepatotoxicity whereas none of the 4 anti-HCV positive patients had hepatotoxicity and no patient was positive for concomitant HBsAg and anti-HCV Ab.</p>
<a id="article1.body1.sec3.sec2.p4" name="article1.body1.sec3.sec2.p4"></a><p>CD4 count was done for the HIV positive patients and multivariate analysis to see the association with development of sub-clinical hepatotoxicity showed that among those patients with different CD4 count when compared with those with &gt;200/mm<sup>3</sup> the odds ratio is 20.5 with a 95% CI (2.1–195.6) for those with 0–50/mm<sup>3</sup>, 5.9 with a 95% CI (0.6–52.2) for those with 51–100/mm<sup>3</sup>, and 4.2 with a 95% CI (0.4–41.7) for those with 101–200/mm<sup>3</sup> (<a href="#pone-0001809-t001">Table 1</a>, <a href="#pone-0001809-t003">3</a> and <a href="#pone-0001809-t004">4</a>). This suggests that as the CD4 count decreases the risk of developing hepatotoxicity also increases.</p>

</div>

<div id="section4" class="section"><a id="s4" name="s4" toc="s4" title="Discussion"></a><h3>Discussion</h3><a id="article1.body1.sec4.p1" name="article1.body1.sec4.p1"></a><p>The proportion of patients with anti-tuberculosis therapy induced hepatotoxicity in general has not been studied that often in African patients. In this study therefore, we studied this common clinical problem among Ethiopian patients. To effectively study this problem we have excluded patients previously treated with anti-tuberculosis drugs, critically sick patients as assessed by level of consciousness and concomitant illnesses, and patients with baseline liver function test (LFT) values above the normal range.</p>
<a id="article1.body1.sec4.p2" name="article1.body1.sec4.p2"></a><p>The proportion of DIH in HIV positive and HIV negative patients was statistically significant where HIV positive patients are at a higher risk than HIV negative ones. Similar findings have been observed in other studies. <a href="#pone.0001809-Ungo1">[13]</a>, <a href="#pone.0001809-PedralSampaio1">[20]</a>, <a href="#pone.0001809-Yee1">[21]</a> This may be partly explained by the different drugs used by these patients for the treatment of AIDS-related opportunistic infections before the diagnosis of TB was made. Even if the number of patients in the different groups is small we have also observed that development of hepatotoxicity had a statistically significant association with decrement in the immune status of the patients as measured by the CD4 count. This phenomenon was not shown in previous studies and may suggest the presence of an immunologic mechanism for the development of anti-TB DIH although the exact mechanism has not yet been clearly elucidated. <a href="#pone.0001809-Pol1">[22]</a> The other possible explanation for this could be, since patients with low CD4 count are more prone in acquiring opportunistic infections, this might necessitate consumption of different drugs leading to sub clinical liver damage and thereby increase susceptibility for hepatotoxicity while taking anti TB. <a href="#pone.0001809-WHO1">[8]</a>, <a href="#pone.0001809-Mahmood1">[23]</a>, <a href="#pone.0001809-Hoffmann1">[24]</a></p>
<a id="article1.body1.sec4.p3" name="article1.body1.sec4.p3"></a><p>Unlike previous studies which showed that patients in the older age group are at increased risk for development of hepatotoxicity, <a href="#pone.0001809-Ungo1">[13]</a>, <a href="#pone.0001809-PedralSampaio1">[20]</a>, <a href="#pone.0001809-WHO2">[25]</a> in this study, such a finding was not observed and this could be due to a larger proportion of study participants being in the age group below 35 years which will make comparison difficult. However, there are also studies which support that age is not a risk factor for development of hepatotoxicity in patients taking anti-tuberculosis therapy. <a href="#pone.0001809-WHO2">[25]</a>–<a href="#pone.0001809-Anand1">[27]</a></p>
<a id="article1.body1.sec4.p4" name="article1.body1.sec4.p4"></a><p>Malnutrition as a risk factor for DIH was suggested by previous studies. <a href="#pone.0001809-Sharma1">[12]</a>, <a href="#pone.0001809-WHO2">[25]</a> However, in this study we did not see any significant association between malnutrition as measured by BMI and DIH. Perhaps this may be because of the larger proportion of study participants having a lower BMI making comparison difficult. Moreover, similar findings were seen in some other studies. <a href="#pone.0001809-Pol1">[22]</a>, <a href="#pone.0001809-Shakya1">[26]</a></p>
<a id="article1.body1.sec4.p5" name="article1.body1.sec4.p5"></a><p>Being alcoholic is one of the well established risk factors for DIH. <a href="#pone.0001809-Sharma1">[12]</a>, <a href="#pone.0001809-Yee1">[21]</a>, <a href="#pone.0001809-Pol1">[22]</a>, <a href="#pone.0001809-Shakya1">[26]</a> In our study however, we did not see this association. The reason for this is that even if 74 patients replied that they have history of alcohol intake it is possible that the levels of alcohol consumption were not high enough to contribute to hepatotoxicity.</p>
<a id="article1.body1.sec4.p6" name="article1.body1.sec4.p6"></a><p>We have also observed that patients who took drugs concomitantly with the anti-tuberculosis therapy were at risk for the development of hepatotoxicity. This could be because of the synergistic hepatotoxic effect caused by the other drugs. Similar finding was observed while combining different drugs. <a href="#pone.0001809-Yee1">[21]</a>, <a href="#pone.0001809-Koju1">[28]</a></p>
<a id="article1.body1.sec4.p7" name="article1.body1.sec4.p7"></a><p>Unlike other studies no association between Anti-HCV and HBsAg positivity and development of hepatotoxicity was observed. <a href="#pone.0001809-Ungo1">[13]</a>, <a href="#pone.0001809-Shakya1">[26]</a>, <a href="#pone.0001809-Sturgill1">[29]</a>, <a href="#pone.0001809-Pan1">[30]</a> This may be attributed to the small number of patients who are positive for Anti-HCV antibody and HBsAg in this study.</p>
<a id="article1.body1.sec4.p8" name="article1.body1.sec4.p8"></a><p>This study was conducted at the time were there was no free antiretroviral drug provision currently however, ART is being given for free to all those who are in need. The result of this study might have been affected if there was concurrent treatment with ART. Findings of this study therefore, would act as a background for studies that have aimed at identifying risk factors for DIH while patients take ART and anti-TB drugs concomitantly.</p>
<a id="article1.body1.sec4.p9" name="article1.body1.sec4.p9"></a><p>In general we have tried to explore the different risk factors for the development of anti-tuberculosis DIH in newly diagnosed TB patients from Ethiopia. We recommend that patients with HIV infection, low CD4 count and those on other concomitant drugs have initial screening with liver function test and closely monitored with subsequent tests during treatment.</p>
<a id="article1.body1.sec4.p10" name="article1.body1.sec4.p10"></a><p>We also recommend that further studies should be conducted to explore the detail mechanism as to why this identified risk factors contribute for development of hepatotoxicity and also further asses those risk factors that are not addresses in this study in detailed.</p>

<h4>Limitations of the study</h4>
<a id="article1.body1.sec4.sec1.p1" name="article1.body1.sec4.sec1.p1"></a><p>Since the main objective of this study was to asses the effect of HIV infection on development of hepatotoxicity. The sample size was therefore calculated considering HIV positive and HIV negative patients. As a result it was difficult to make strong association on different parameters such as association of hepatotoxicity with HbsAg, Anti-HCV Antibody and CD4 count. Moreover, since the majority of our study participants were underweight it was difficult to see the association between BMI and hepatotoxicity. The other limitation of the study was representatives. Since the study was conducted only in one health institution which was also located in one city there might be a problem of representing the whole country with regard to economic status and ethnic group.</p>

</div>





<div><a id="ack" name="ack" toc="ack" title="Acknowledgments"></a><h3>Acknowledgments</h3>
<a id="article1.back1.ack1.p1" name="article1.back1.ack1.p1"></a><p>We would like to thank all the staffs of Armauer Hansen Research Institute (AHRI) and St. Peter's TB Specialized Hospital, Addis Ababa, Ethiopia, for their unreserved support and special thanks goes to Dr. Howard Engers, the director of AHRI who have been giving magnificent advises and comments starting from the inception till completion of the study. This study was conducted in Ethiopia.</p>
</div><div class="contributions"><a id="authcontrib" name="authcontrib" toc="authcontrib" title="Author Contributions"></a><h3>Author Contributions</h3><p>Conceived and designed the experiments: GA LY GY WA EM EA LL AA. Performed the experiments: BF GY EA. Analyzed the data: GA LY GY WA EM EA LL AA. Contributed reagents/materials/analysis tools: EA LL AA. Wrote the paper: GA LY GY WA EM EA LL AA.</p></div><div><a id="references" name="references" toc="references" title="References"></a><h3>References</h3><ol class="references"><li><span class="label">1.
              </span><a name="pone.0001809-Dye1" id="pone.0001809-Dye1"></a>Dye C, Scheele S, Dolin P, Pathania V, Raviglione MC (1999) Consensus statement. Global burden of tuberculosis: estimated incidence, prevalence, and mortality by country. WHO Global Surveillance and Monitoring Project. JAMA  282: 677–686.  <ul class="find" data-citedArticleID="1075722"><li><a href="http://www.crossref.org/guestquery/?auth2=&amp;atitle2=Consensus+statement.+Global+burden+of+tuberculosis%3A+estimated+incidence%2C+prevalence%2C+and+mortality+by+country.+WHO+Global+Surveillance+and+Monitoring+Project.&amp;auth=&amp;atitle=Consensus+statement.+Global+burden+of+tuberculosis%3A+estimated+incidence%2C+prevalence%2C+and+mortality+by+country.+WHO+Global+Surveillance+and+Monitoring+Project." target="_new" title="Go to article in CrossRef">
                          View Article
                        </a></li><li><a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&amp;cmd=Search&amp;doptcmdl=Citation&amp;defaultField=Title+Word&amp;term=Consensus+statement.+Global+burden+of+tuberculosis%3A+estimated+incidence%2C+prevalence%2C+and+mortality+by+country.+WHO+Global+Surveillance+and+Monitoring+Project." target="_new" title="Go to article in PubMed">
                          PubMed/NCBI
                        </a></li><li><a href="http://scholar.google.com/scholar?hl=en&amp;safe=off&amp;q=%22Consensus+statement.+Global+burden+of+tuberculosis%3A+estimated+incidence%2C+prevalence%2C+and+mortality+by+country.+WHO+Global+Surveillance+and+Monitoring+Project.%22" target="_new" title="Go to article in Google Scholar">
                          Google Scholar
                        </a></li></ul></li><li><span class="label">2.
              </span><a name="pone.0001809-Yepes1" id="pone.0001809-Yepes1"></a>Yepes JF, Sullivan J, Pinto A (2004) Tuberculosis: medical management update. Oral Surg Oral Med Oral Pathol Oral Radiol Endod  98: 267–273.  <ul class="find" data-citedArticleID="1075764" data-doi="10.1016/j.tripleo.2004.05.012"><li><a href="http://dx.doi.org/10.1016/j.tripleo.2004.05.012" target="_new" title="Go to article in CrossRef">
                          View Article
                        </a></li><li><a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&amp;cmd=Search&amp;doptcmdl=Citation&amp;defaultField=Title+Word&amp;term=Tuberculosis%3A+medical+management+update." target="_new" title="Go to article in PubMed">
                          PubMed/NCBI
                        </a></li><li><a href="http://scholar.google.com/scholar?hl=en&amp;safe=off&amp;q=%22Tuberculosis%3A+medical+management+update.%22" target="_new" title="Go to article in Google Scholar">
                          Google Scholar
                        </a></li></ul></li><li><span class="label">3.
              </span><a name="pone.0001809-Brewer1" id="pone.0001809-Brewer1"></a>Brewer TF, Heymann J (2004) To control and beyond: moving towards eliminating the global tuberculosis threat. J Epidemiol Community Health  58: 822–825.  <ul class="find" data-citedArticleID="1075714" data-doi="10.1136/jech.2003.008664"><li><a href="http://dx.doi.org/10.1136/jech.2003.008664" target="_new" title="Go to article in CrossRef">
                          View Article
                        </a></li><li><a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&amp;cmd=Search&amp;doptcmdl=Citation&amp;defaultField=Title+Word&amp;term=To+control+and+beyond%3A+moving+towards+eliminating+the+global+tuberculosis+threat." target="_new" title="Go to article in PubMed">
                          PubMed/NCBI
                        </a></li><li><a href="http://scholar.google.com/scholar?hl=en&amp;safe=off&amp;q=%22To+control+and+beyond%3A+moving+towards+eliminating+the+global+tuberculosis+threat.%22" target="_new" title="Go to article in Google Scholar">
                          Google Scholar
                        </a></li></ul></li><li><span class="label">4.
              </span><a name="pone.0001809-Aaron1" id="pone.0001809-Aaron1"></a>Aaron L, Saadoun D, Calatroni I, Launay O, Emain N, et al.  (2004) Tuberculosis in HIV-infected patients: a comprehensive review. Clin Microbiol Infect  10: 388–398.  <ul class="find" data-citedArticleID="1075704" data-doi="10.1111/j.1469-0691.2004.00758.x"><li><a href="http://dx.doi.org/10.1111/j.1469-0691.2004.00758.x" target="_new" title="Go to article in CrossRef">
                          View Article
                        </a></li><li><a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&amp;cmd=Search&amp;doptcmdl=Citation&amp;defaultField=Title+Word&amp;term=Tuberculosis+in+HIV-infected+patients%3A+a+comprehensive+review." target="_new" title="Go to article in PubMed">
                          PubMed/NCBI
                        </a></li><li><a href="http://scholar.google.com/scholar?hl=en&amp;safe=off&amp;q=%22Tuberculosis+in+HIV-infected+patients%3A+a+comprehensive+review.%22" target="_new" title="Go to article in Google Scholar">
                          Google Scholar
                        </a></li></ul></li><li><span class="label">5.
              </span><a name="pone.0001809-Bassey1" id="pone.0001809-Bassey1"></a>Bassey EB, Momoh MA, Imadiyi SO, Udofia EB, Miri FS, et al.  (2005) The trend of pulmonary tuberculosis in patients seen at DOTS clinics in the Federal Capital Territory, Abuja, Nigeria. Public  Health119: 405–408.  <ul class="find" data-citedArticleID="1075712" data-doi="10.1016/j.puhe.2004.05.012"><li><a href="http://dx.doi.org/10.1016/j.puhe.2004.05.012" target="_new" title="Go to article in CrossRef">
                          View Article
                        </a></li><li><a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&amp;cmd=Search&amp;doptcmdl=Citation&amp;defaultField=Title+Word&amp;term=The+trend+of+pulmonary+tuberculosis+in+patients+seen+at+DOTS+clinics+in+the+Federal+Capital+Territory%2C+Abuja%2C+Nigeria." target="_new" title="Go to article in PubMed">
                          PubMed/NCBI
                        </a></li><li><a href="http://scholar.google.com/scholar?hl=en&amp;safe=off&amp;q=%22The+trend+of+pulmonary+tuberculosis+in+patients+seen+at+DOTS+clinics+in+the+Federal+Capital+Territory%2C+Abuja%2C+Nigeria.%22" target="_new" title="Go to article in Google Scholar">
                          Google Scholar
                        </a></li></ul></li><li><span class="label">6.
              </span><a name="pone.0001809-Gooze1" id="pone.0001809-Gooze1"></a>Gooze L (2003) Tuberculosis and HIV. Current American Thoracic Society/CDC Treatment Recommendation.  <ul class="find" data-citedArticleID="1075726"><li><a href="http://www.crossref.org/guestquery/?auth2=&amp;atitle2=Tuberculosis+and+HIV.+Current+American+Thoracic+Society%2FCDC+Treatment+Recommendation.&amp;auth=&amp;atitle=Tuberculosis+and+HIV.+Current+American+Thoracic+Society%2FCDC+Treatment+Recommendation." target="_new" title="Go to article in CrossRef">
                          View Article
                        </a></li><li><a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&amp;cmd=Search&amp;doptcmdl=Citation&amp;defaultField=Title+Word&amp;term=Tuberculosis+and+HIV.+Current+American+Thoracic+Society%2FCDC+Treatment+Recommendation." target="_new" title="Go to article in PubMed">
                          PubMed/NCBI
                        </a></li><li><a href="http://scholar.google.com/scholar?hl=en&amp;safe=off&amp;q=%22Tuberculosis+and+HIV.+Current+American+Thoracic+Society%2FCDC+Treatment+Recommendation.%22" target="_new" title="Go to article in Google Scholar">
                          Google Scholar
                        </a></li></ul></li><li><span class="label">7.
              </span><a name="pone.0001809-Focusdisease1" id="pone.0001809-Focusdisease1"></a>Focus/disease watch (2004) Tuberculosis. Nature reviews/microbiology  2: 930–932.  <ul class="find" data-citedArticleID="1075724" data-doi="10.1038/nrmicro1050"><li><a href="http://dx.doi.org/10.1038/nrmicro1050" target="_new" title="Go to article in CrossRef">
                          View Article
                        </a></li><li><a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&amp;cmd=Search&amp;doptcmdl=Citation&amp;defaultField=Title+Word&amp;term=Tuberculosis." target="_new" title="Go to article in PubMed">
                          PubMed/NCBI
                        </a></li><li><a href="http://scholar.google.com/scholar?hl=en&amp;safe=off&amp;q=%22Tuberculosis.%22" target="_new" title="Go to article in Google Scholar">
                          Google Scholar
                        </a></li></ul></li><li><span class="label">8.
              </span><a name="pone.0001809-WHO1" id="pone.0001809-WHO1"></a>WHO (2004) TB/HIV A CLINICAL MANUAL  <ul class="find" data-citedArticleID="1075758"><li><a href="http://www.crossref.org/guestquery/?auth2=&amp;atitle2=TB%2FHIV+A+CLINICAL+MANUAL&amp;auth=&amp;atitle=TB%2FHIV+A+CLINICAL+MANUAL" target="_new" title="Go to article in CrossRef">
                          View Article
                        </a></li><li><a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&amp;cmd=Search&amp;doptcmdl=Citation&amp;defaultField=Title+Word&amp;term=TB%2FHIV+A+CLINICAL+MANUAL" target="_new" title="Go to article in PubMed">
                          PubMed/NCBI
                        </a></li><li><a href="http://scholar.google.com/scholar?hl=en&amp;safe=off&amp;q=%22TB%2FHIV+A+CLINICAL+MANUAL%22" target="_new" title="Go to article in Google Scholar">
                          Google Scholar
                        </a></li></ul></li><li><span class="label">9.
              </span><a name="pone.0001809-Ali1" id="pone.0001809-Ali1"></a>Ali J (1996) Hepatotoxic effects of tuberculosis therapy. A practical approach to a tricky management problem. Postgrad Med  99: 217–220.230–231, 235–236  <ul class="find" data-citedArticleID="1075706"><li><a href="http://www.crossref.org/guestquery/?auth2=&amp;atitle2=Hepatotoxic+effects+of+tuberculosis+therapy.+A+practical+approach+to+a+tricky+management+problem.&amp;auth=&amp;atitle=Hepatotoxic+effects+of+tuberculosis+therapy.+A+practical+approach+to+a+tricky+management+problem." target="_new" title="Go to article in CrossRef">
                          View Article
                        </a></li><li><a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&amp;cmd=Search&amp;doptcmdl=Citation&amp;defaultField=Title+Word&amp;term=Hepatotoxic+effects+of+tuberculosis+therapy.+A+practical+approach+to+a+tricky+management+problem." target="_new" title="Go to article in PubMed">
                          PubMed/NCBI
                        </a></li><li><a href="http://scholar.google.com/scholar?hl=en&amp;safe=off&amp;q=%22Hepatotoxic+effects+of+tuberculosis+therapy.+A+practical+approach+to+a+tricky+management+problem.%22" target="_new" title="Go to article in Google Scholar">
                          Google Scholar
                        </a></li></ul></li><li><span class="label">10.
              </span><a name="pone.0001809-Cheukming1" id="pone.0001809-Cheukming1"></a>Cheuk-ming T (2002) MONITORING FOR HEPATOTOXICITY DURING ANTITUBERCULOSIS TREATMENT  <ul class="find" data-citedArticleID="1075720"><li><a href="http://www.crossref.org/guestquery/?auth2=&amp;atitle2=MONITORING+FOR+HEPATOTOXICITY+DURING+ANTITUBERCULOSIS+TREATMENT&amp;auth=&amp;atitle=MONITORING+FOR+HEPATOTOXICITY+DURING+ANTITUBERCULOSIS+TREATMENT" target="_new" title="Go to article in CrossRef">
                          View Article
                        </a></li><li><a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&amp;cmd=Search&amp;doptcmdl=Citation&amp;defaultField=Title+Word&amp;term=MONITORING+FOR+HEPATOTOXICITY+DURING+ANTITUBERCULOSIS+TREATMENT" target="_new" title="Go to article in PubMed">
                          PubMed/NCBI
                        </a></li><li><a href="http://scholar.google.com/scholar?hl=en&amp;safe=off&amp;q=%22MONITORING+FOR+HEPATOTOXICITY+DURING+ANTITUBERCULOSIS+TREATMENT%22" target="_new" title="Go to article in Google Scholar">
                          Google Scholar
                        </a></li></ul></li><li><span class="label">11.
              </span><a name="pone.0001809-Huang1" id="pone.0001809-Huang1"></a>Huang YS, Chern HD, Su WJ, Wu JC, Chang SC, et al.  (2003) Cytochrome P450 2E1 genotype and the susceptibility to antituberculosis drug-induced hepatitis. Hepatology  37: 924–930.  <ul class="find" data-citedArticleID="1075732" data-doi="10.1053/jhep.2003.50144"><li><a href="http://dx.doi.org/10.1053/jhep.2003.50144" target="_new" title="Go to article in CrossRef">
                          View Article
                        </a></li><li><a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&amp;cmd=Search&amp;doptcmdl=Citation&amp;defaultField=Title+Word&amp;term=Cytochrome+P450+2E1+genotype+and+the+susceptibility+to+antituberculosis+drug-induced+hepatitis." target="_new" title="Go to article in PubMed">
                          PubMed/NCBI
                        </a></li><li><a href="http://scholar.google.com/scholar?hl=en&amp;safe=off&amp;q=%22Cytochrome+P450+2E1+genotype+and+the+susceptibility+to+antituberculosis+drug-induced+hepatitis.%22" target="_new" title="Go to article in Google Scholar">
                          Google Scholar
                        </a></li></ul></li><li><span class="label">12.
              </span><a name="pone.0001809-Sharma1" id="pone.0001809-Sharma1"></a>Sharma SK, Balamurugan A, Saha PK, Pandey RM, Mehra NK (2002) Evaluation of clinical and immunogenetic risk factors for the development of hepatotoxicity during antituberculosis treatment. Am J Respir Crit Care Med  166: 916–919.  <ul class="find" data-citedArticleID="1075752" data-doi="10.1164/rccm.2108091"><li><a href="http://dx.doi.org/10.1164/rccm.2108091" target="_new" title="Go to article in CrossRef">
                          View Article
                        </a></li><li><a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&amp;cmd=Search&amp;doptcmdl=Citation&amp;defaultField=Title+Word&amp;term=Evaluation+of+clinical+and+immunogenetic+risk+factors+for+the+development+of+hepatotoxicity+during+antituberculosis+treatment." target="_new" title="Go to article in PubMed">
                          PubMed/NCBI
                        </a></li><li><a href="http://scholar.google.com/scholar?hl=en&amp;safe=off&amp;q=%22Evaluation+of+clinical+and+immunogenetic+risk+factors+for+the+development+of+hepatotoxicity+during+antituberculosis+treatment.%22" target="_new" title="Go to article in Google Scholar">
                          Google Scholar
                        </a></li></ul></li><li><span class="label">13.
              </span><a name="pone.0001809-Ungo1" id="pone.0001809-Ungo1"></a>Ungo JR, Jones D, Ashkin D, Hollender ES, Bernstein D, et al.  (1998) Antituberculosis drug-induced hepatotoxicity. The role of hepatitis C virus and the human immunodeficiency virus. Am J Respir Crit Care Med  157: 1871–1876.  <ul class="find" data-citedArticleID="1075756" data-doi="10.1164/ajrccm.157.6.9711039"><li><a href="http://dx.doi.org/10.1164/ajrccm.157.6.9711039" target="_new" title="Go to article in CrossRef">
                          View Article
                        </a></li><li><a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&amp;cmd=Search&amp;doptcmdl=Citation&amp;defaultField=Title+Word&amp;term=Antituberculosis+drug-induced+hepatotoxicity.+The+role+of+hepatitis+C+virus+and+the+human+immunodeficiency+virus." target="_new" title="Go to article in PubMed">
                          PubMed/NCBI
                        </a></li><li><a href="http://scholar.google.com/scholar?hl=en&amp;safe=off&amp;q=%22Antituberculosis+drug-induced+hepatotoxicity.+The+role+of+hepatitis+C+virus+and+the+human+immunodeficiency+virus.%22" target="_new" title="Go to article in Google Scholar">
                          Google Scholar
                        </a></li></ul></li><li><span class="label">14.
              </span><a name="pone.0001809-Bruchfeld1" id="pone.0001809-Bruchfeld1"></a>Bruchfeld J, Bruchfeld J, Aderaye G, Palme IB, Bjorvatn B, Kallenius G, et al.  (2000) Sputum concentration improves diagnosis of tuberculosis in a setting with a high prevalence of HIV. Trans R Soc Trop Med Hyg  94: 677–680.  <ul class="find" data-citedArticleID="1075716" data-doi="10.1016/s0035-9203(00)90230-x"><li><a href="http://dx.doi.org/10.1016/s0035-9203(00)90230-x" target="_new" title="Go to article in CrossRef">
                          View Article
                        </a></li><li><a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&amp;cmd=Search&amp;doptcmdl=Citation&amp;defaultField=Title+Word&amp;term=Sputum+concentration+improves+diagnosis+of+tuberculosis+in+a+setting+with+a+high+prevalence+of+HIV." target="_new" title="Go to article in PubMed">
                          PubMed/NCBI
                        </a></li><li><a href="http://scholar.google.com/scholar?hl=en&amp;safe=off&amp;q=%22Sputum+concentration+improves+diagnosis+of+tuberculosis+in+a+setting+with+a+high+prevalence+of+HIV.%22" target="_new" title="Go to article in Google Scholar">
                          Google Scholar
                        </a></li></ul></li><li><span class="label">15.
              </span><a name="pone.0001809-Kimmoun1" id="pone.0001809-Kimmoun1"></a>Kimmoun E, Samuel D (2002) Antituberculous drugs in patients with chronic liver disease. J Gastroenterol Hepatol  17: S408–S412.  <ul class="find" data-citedArticleID="1075734" data-doi="10.1046/j.1440-1746.17.s3.36.x"><li><a href="http://dx.doi.org/10.1046/j.1440-1746.17.s3.36.x" target="_new" title="Go to article in CrossRef">
                          View Article
                        </a></li><li><a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&amp;cmd=Search&amp;doptcmdl=Citation&amp;defaultField=Title+Word&amp;term=Antituberculous+drugs+in+patients+with+chronic+liver+disease." target="_new" title="Go to article in PubMed">
                          PubMed/NCBI
                        </a></li><li><a href="http://scholar.google.com/scholar?hl=en&amp;safe=off&amp;q=%22Antituberculous+drugs+in+patients+with+chronic+liver+disease.%22" target="_new" title="Go to article in Google Scholar">
                          Google Scholar
                        </a></li></ul></li><li><span class="label">16.
              </span><a name="pone.0001809-Barnes1" id="pone.0001809-Barnes1"></a>Barnes PF, Barrows SA (1993) Tuberculosis in the 1990s. Ann Intern Med  119: 400–410.  <ul class="find" data-citedArticleID="1075710" data-doi="10.7326/0003-4819-119-5-199309010-00009"><li><a href="http://dx.doi.org/10.7326/0003-4819-119-5-199309010-00009" target="_new" title="Go to article in CrossRef">
                          View Article
                        </a></li><li><a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&amp;cmd=Search&amp;doptcmdl=Citation&amp;defaultField=Title+Word&amp;term=Tuberculosis+in+the+1990s." target="_new" title="Go to article in PubMed">
                          PubMed/NCBI
                        </a></li><li><a href="http://scholar.google.com/scholar?hl=en&amp;safe=off&amp;q=%22Tuberculosis+in+the+1990s.%22" target="_new" title="Go to article in Google Scholar">
                          Google Scholar
                        </a></li></ul></li><li><span class="label">17.
              </span><a name="pone.0001809-CamposFranco1" id="pone.0001809-CamposFranco1"></a>Campos-Franco JA, Gonzalez-Quintela , Alende-Sixto MR (2004) Isoniazid-induced hyperacute liver failure in a young patient receiving carbamazepine. Eur J Intern Med  15: 396–397.  <ul class="find" data-citedArticleID="1075718" data-doi="10.1016/j.ejim.2004.07.005"><li><a href="http://dx.doi.org/10.1016/j.ejim.2004.07.005" target="_new" title="Go to article in CrossRef">
                          View Article
                        </a></li><li><a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&amp;cmd=Search&amp;doptcmdl=Citation&amp;defaultField=Title+Word&amp;term=Isoniazid-induced+hyperacute+liver+failure+in+a+young+patient+receiving+carbamazepine." target="_new" title="Go to article in PubMed">
                          PubMed/NCBI
                        </a></li><li><a href="http://scholar.google.com/scholar?hl=en&amp;safe=off&amp;q=%22Isoniazid-induced+hyperacute+liver+failure+in+a+young+patient+receiving+carbamazepine.%22" target="_new" title="Go to article in Google Scholar">
                          Google Scholar
                        </a></li></ul></li><li><span class="label">18.
              </span><a name="pone.0001809-Ozick1" id="pone.0001809-Ozick1"></a>Ozick LA, Jacob L, Comer GM, Lee TP, Ben-Zvi J, et al.  (1995) Hepatotoxicity from isoniazid and rifampin in inner-city AIDS patients. Am J Gastroenterol  90: 1978–1980.  <ul class="find" data-citedArticleID="1075742"><li><a href="http://www.crossref.org/guestquery/?auth2=&amp;atitle2=Hepatotoxicity+from+isoniazid+and+rifampin+in+inner-city+AIDS+patients.&amp;auth=&amp;atitle=Hepatotoxicity+from+isoniazid+and+rifampin+in+inner-city+AIDS+patients." target="_new" title="Go to article in CrossRef">
                          View Article
                        </a></li><li><a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&amp;cmd=Search&amp;doptcmdl=Citation&amp;defaultField=Title+Word&amp;term=Hepatotoxicity+from+isoniazid+and+rifampin+in+inner-city+AIDS+patients." target="_new" title="Go to article in PubMed">
                          PubMed/NCBI
                        </a></li><li><a href="http://scholar.google.com/scholar?hl=en&amp;safe=off&amp;q=%22Hepatotoxicity+from+isoniazid+and+rifampin+in+inner-city+AIDS+patients.%22" target="_new" title="Go to article in Google Scholar">
                          Google Scholar
                        </a></li></ul></li><li><span class="label">19.
              </span><a name="pone.0001809-Gross1" id="pone.0001809-Gross1"></a>Gross M, Kruisselbrink T, Anderson K, Lang N, McGovern P, et al.  (1999) Distribution and concordance of N-acetyltransferase genotype and phenotype in an American population. Cancer Epidemiol Biomarkers Prev  8: 683–692.  <ul class="find" data-citedArticleID="1075728"><li><a href="http://www.crossref.org/guestquery/?auth2=&amp;atitle2=Distribution+and+concordance+of+N-acetyltransferase+genotype+and+phenotype+in+an+American+population.&amp;auth=&amp;atitle=Distribution+and+concordance+of+N-acetyltransferase+genotype+and+phenotype+in+an+American+population." target="_new" title="Go to article in CrossRef">
                          View Article
                        </a></li><li><a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&amp;cmd=Search&amp;doptcmdl=Citation&amp;defaultField=Title+Word&amp;term=Distribution+and+concordance+of+N-acetyltransferase+genotype+and+phenotype+in+an+American+population." target="_new" title="Go to article in PubMed">
                          PubMed/NCBI
                        </a></li><li><a href="http://scholar.google.com/scholar?hl=en&amp;safe=off&amp;q=%22Distribution+and+concordance+of+N-acetyltransferase+genotype+and+phenotype+in+an+American+population.%22" target="_new" title="Go to article in Google Scholar">
                          Google Scholar
                        </a></li></ul></li><li><span class="label">20.
              </span><a name="pone.0001809-PedralSampaio1" id="pone.0001809-PedralSampaio1"></a>Pedral-Sampaio DB, Alves CR, Netto EM, Brites C, Oliveira AS, et al.  (2004) Efficacy and safety of Efavirenz in HIV patients on Rifampin for tuberculosis. Braz J Infect Dis  8: 211–216.  <ul class="find" data-citedArticleID="1075746" data-doi="10.1590/s1413-86702004000300004"><li><a href="http://dx.doi.org/10.1590/s1413-86702004000300004" target="_new" title="Go to article in CrossRef">
                          View Article
                        </a></li><li><a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&amp;cmd=Search&amp;doptcmdl=Citation&amp;defaultField=Title+Word&amp;term=Efficacy+and+safety+of+Efavirenz+in+HIV+patients+on+Rifampin+for+tuberculosis." target="_new" title="Go to article in PubMed">
                          PubMed/NCBI
                        </a></li><li><a href="http://scholar.google.com/scholar?hl=en&amp;safe=off&amp;q=%22Efficacy+and+safety+of+Efavirenz+in+HIV+patients+on+Rifampin+for+tuberculosis.%22" target="_new" title="Go to article in Google Scholar">
                          Google Scholar
                        </a></li></ul></li><li><span class="label">21.
              </span><a name="pone.0001809-Yee1" id="pone.0001809-Yee1"></a>Yee D, Valiquette C, Pelletier M, Parisien I, Rocher I, et al.  (2003) Incidence of serious side effects from first-line antituberculosis drugs among patients treated for active tuberculosis. Am J Respir Crit Care Med  167: 1472–1477.  <ul class="find" data-citedArticleID="1075762" data-doi="10.1164/rccm.200206-626oc"><li><a href="http://dx.doi.org/10.1164/rccm.200206-626oc" target="_new" title="Go to article in CrossRef">
                          View Article
                        </a></li><li><a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&amp;cmd=Search&amp;doptcmdl=Citation&amp;defaultField=Title+Word&amp;term=Incidence+of+serious+side+effects+from+first-line+antituberculosis+drugs+among+patients+treated+for+active+tuberculosis." target="_new" title="Go to article in PubMed">
                          PubMed/NCBI
                        </a></li><li><a href="http://scholar.google.com/scholar?hl=en&amp;safe=off&amp;q=%22Incidence+of+serious+side+effects+from+first-line+antituberculosis+drugs+among+patients+treated+for+active+tuberculosis.%22" target="_new" title="Go to article in Google Scholar">
                          Google Scholar
                        </a></li></ul></li><li><span class="label">22.
              </span><a name="pone.0001809-Pol1" id="pone.0001809-Pol1"></a>Pol S, Lebray P, Vallet-Pichard A (2004) HIV Infection and Hepatic Enzyme Abnormalities: Intricacies of the Pathogenic Mechanisms. Clinical Infectious Diseases  38: 65–72.  <ul class="find" data-citedArticleID="1075748" data-doi="10.1086/381499"><li><a href="http://dx.doi.org/10.1086/381499" target="_new" title="Go to article in CrossRef">
                          View Article
                        </a></li><li><a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&amp;cmd=Search&amp;doptcmdl=Citation&amp;defaultField=Title+Word&amp;term=HIV+Infection+and+Hepatic+Enzyme+Abnormalities%3A+Intricacies+of+the+Pathogenic+Mechanisms." target="_new" title="Go to article in PubMed">
                          PubMed/NCBI
                        </a></li><li><a href="http://scholar.google.com/scholar?hl=en&amp;safe=off&amp;q=%22HIV+Infection+and+Hepatic+Enzyme+Abnormalities%3A+Intricacies+of+the+Pathogenic+Mechanisms.%22" target="_new" title="Go to article in Google Scholar">
                          Google Scholar
                        </a></li></ul></li><li><span class="label">23.
              </span><a name="pone.0001809-Mahmood1" id="pone.0001809-Mahmood1"></a>Mahmood K, Hussain A, Jairamani KL, Talib A, Abbasi B, et al.  (2007) Hepatotoxicity with antituberculosis drugs: the risk factors. Pak J Med Sci  23: 33–38.  <ul class="find" data-citedArticleID="1075740"><li><a href="http://www.crossref.org/guestquery/?auth2=&amp;atitle2=Hepatotoxicity+with+antituberculosis+drugs%3A+the+risk+factors.&amp;auth=&amp;atitle=Hepatotoxicity+with+antituberculosis+drugs%3A+the+risk+factors." target="_new" title="Go to article in CrossRef">
                          View Article
                        </a></li><li><a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&amp;cmd=Search&amp;doptcmdl=Citation&amp;defaultField=Title+Word&amp;term=Hepatotoxicity+with+antituberculosis+drugs%3A+the+risk+factors." target="_new" title="Go to article in PubMed">
                          PubMed/NCBI
                        </a></li><li><a href="http://scholar.google.com/scholar?hl=en&amp;safe=off&amp;q=%22Hepatotoxicity+with+antituberculosis+drugs%3A+the+risk+factors.%22" target="_new" title="Go to article in Google Scholar">
                          Google Scholar
                        </a></li></ul></li><li><span class="label">24.
              </span><a name="pone.0001809-Hoffmann1" id="pone.0001809-Hoffmann1"></a>Hoffmann C, Rockstroh JK, Kamps BSHIV Medicine 2006. 2006: p. 395–480  <ul class="find" data-citedArticleID="1075730"><li><a href="http://www.crossref.org/guestquery/?auth2=&amp;atitle2=HIV+Medicine+2006.+2006%3A+p.+395%3F480&amp;auth=&amp;atitle=HIV+Medicine+2006.+2006%3A+p.+395%3F480" target="_new" title="Go to article in CrossRef">
                          View Article
                        </a></li><li><a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&amp;cmd=Search&amp;doptcmdl=Citation&amp;defaultField=Title+Word&amp;term=HIV+Medicine+2006.+2006%3A+p.+395%E2%80%93480" target="_new" title="Go to article in PubMed">
                          PubMed/NCBI
                        </a></li><li><a href="http://scholar.google.com/scholar?hl=en&amp;safe=off&amp;q=%22HIV+Medicine+2006.+2006%3A+p.+395%E2%80%93480%22" target="_new" title="Go to article in Google Scholar">
                          Google Scholar
                        </a></li></ul></li><li><span class="label">25.
              </span><a name="pone.0001809-WHO2" id="pone.0001809-WHO2"></a>WHO (2006) antiretroviral therapy for HIV infection in adults and adolescents: Recommendations for a public health approach.  <ul class="find" data-citedArticleID="1075760"><li><a href="http://www.crossref.org/guestquery/?auth2=&amp;atitle2=antiretroviral+therapy+for+HIV+infection+in+adults+and+adolescents%3A+Recommendations+for+a+public+health+approach.&amp;auth=&amp;atitle=antiretroviral+therapy+for+HIV+infection+in+adults+and+adolescents%3A+Recommendations+for+a+public+health+approach." target="_new" title="Go to article in CrossRef">
                          View Article
                        </a></li><li><a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&amp;cmd=Search&amp;doptcmdl=Citation&amp;defaultField=Title+Word&amp;term=antiretroviral+therapy+for+HIV+infection+in+adults+and+adolescents%3A+Recommendations+for+a+public+health+approach." target="_new" title="Go to article in PubMed">
                          PubMed/NCBI
                        </a></li><li><a href="http://scholar.google.com/scholar?hl=en&amp;safe=off&amp;q=%22antiretroviral+therapy+for+HIV+infection+in+adults+and+adolescents%3A+Recommendations+for+a+public+health+approach.%22" target="_new" title="Go to article in Google Scholar">
                          Google Scholar
                        </a></li></ul></li><li><span class="label">26.
              </span><a name="pone.0001809-Shakya1" id="pone.0001809-Shakya1"></a>Shakya R, Rao BS, Shrestha B (2006) Evaluation of risk factors for antituberculosis drugs-induced hepatotoxicity in Nepalese population. Kathmandu university journal of science, engineering and technology  II: 1–8.  <ul class="find" data-citedArticleID="1075750"><li><a href="http://www.crossref.org/guestquery/?auth2=&amp;atitle2=Evaluation+of+risk+factors+for+antituberculosis+drugs-induced+hepatotoxicity+in+Nepalese+population.&amp;auth=&amp;atitle=Evaluation+of+risk+factors+for+antituberculosis+drugs-induced+hepatotoxicity+in+Nepalese+population." target="_new" title="Go to article in CrossRef">
                          View Article
                        </a></li><li><a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&amp;cmd=Search&amp;doptcmdl=Citation&amp;defaultField=Title+Word&amp;term=Evaluation+of+risk+factors+for+antituberculosis+drugs-induced+hepatotoxicity+in+Nepalese+population." target="_new" title="Go to article in PubMed">
                          PubMed/NCBI
                        </a></li><li><a href="http://scholar.google.com/scholar?hl=en&amp;safe=off&amp;q=%22Evaluation+of+risk+factors+for+antituberculosis+drugs-induced+hepatotoxicity+in+Nepalese+population.%22" target="_new" title="Go to article in Google Scholar">
                          Google Scholar
                        </a></li></ul></li><li><span class="label">27.
              </span><a name="pone.0001809-Anand1" id="pone.0001809-Anand1"></a>Anand A, Seth AK, Paul M (2006) Risk Factors of Hepatotoxicity During Anti-tuberculosis Treatment. MJAFI  62: 45–49.  <ul class="find" data-citedArticleID="1075708" data-doi="10.1016/s0377-1237(06)80155-3"><li><a href="http://dx.doi.org/10.1016/s0377-1237(06)80155-3" target="_new" title="Go to article in CrossRef">
                          View Article
                        </a></li><li><a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&amp;cmd=Search&amp;doptcmdl=Citation&amp;defaultField=Title+Word&amp;term=Risk+Factors+of+Hepatotoxicity+During+Anti-tuberculosis+Treatment." target="_new" title="Go to article in PubMed">
                          PubMed/NCBI
                        </a></li><li><a href="http://scholar.google.com/scholar?hl=en&amp;safe=off&amp;q=%22Risk+Factors+of+Hepatotoxicity+During+Anti-tuberculosis+Treatment.%22" target="_new" title="Go to article in Google Scholar">
                          Google Scholar
                        </a></li></ul></li><li><span class="label">28.
              </span><a name="pone.0001809-Koju1" id="pone.0001809-Koju1"></a>Koju D, Rao BS, Shrestha B, Shakya R, Makaju R (2005) Occurrence of side effects from anti-tuberculosis drugs in urban Nepalese population under dots treatment. Kathmandu university journal of science, engineering and technology  1(1):   <ul class="find" data-citedArticleID="1075736"><li><a href="http://www.crossref.org/guestquery/?auth2=&amp;atitle2=Occurrence+of+side+effects+from+anti-tuberculosis+drugs+in+urban+Nepalese+population+under+dots+treatment.&amp;auth=&amp;atitle=Occurrence+of+side+effects+from+anti-tuberculosis+drugs+in+urban+Nepalese+population+under+dots+treatment." target="_new" title="Go to article in CrossRef">
                          View Article
                        </a></li><li><a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&amp;cmd=Search&amp;doptcmdl=Citation&amp;defaultField=Title+Word&amp;term=Occurrence+of+side+effects+from+anti-tuberculosis+drugs+in+urban+Nepalese+population+under+dots+treatment." target="_new" title="Go to article in PubMed">
                          PubMed/NCBI
                        </a></li><li><a href="http://scholar.google.com/scholar?hl=en&amp;safe=off&amp;q=%22Occurrence+of+side+effects+from+anti-tuberculosis+drugs+in+urban+Nepalese+population+under+dots+treatment.%22" target="_new" title="Go to article in Google Scholar">
                          Google Scholar
                        </a></li></ul></li><li><span class="label">29.
              </span><a name="pone.0001809-Sturgill1" id="pone.0001809-Sturgill1"></a>Sturgill MG, Lambert GH (1997) Xenobiotic-induced hepatotoxicity: mechanisms of liver injury and methods of monitoring hepatic function. Clin Chem  430: 1512–1526.  <ul class="find" data-citedArticleID="1075754"><li><a href="http://www.crossref.org/guestquery/?auth2=&amp;atitle2=Xenobiotic-induced+hepatotoxicity%3A+mechanisms+of+liver+injury+and+methods+of+monitoring+hepatic+function.&amp;auth=&amp;atitle=Xenobiotic-induced+hepatotoxicity%3A+mechanisms+of+liver+injury+and+methods+of+monitoring+hepatic+function." target="_new" title="Go to article in CrossRef">
                          View Article
                        </a></li><li><a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&amp;cmd=Search&amp;doptcmdl=Citation&amp;defaultField=Title+Word&amp;term=Xenobiotic-induced+hepatotoxicity%3A+mechanisms+of+liver+injury+and+methods+of+monitoring+hepatic+function." target="_new" title="Go to article in PubMed">
                          PubMed/NCBI
                        </a></li><li><a href="http://scholar.google.com/scholar?hl=en&amp;safe=off&amp;q=%22Xenobiotic-induced+hepatotoxicity%3A+mechanisms+of+liver+injury+and+methods+of+monitoring+hepatic+function.%22" target="_new" title="Go to article in Google Scholar">
                          Google Scholar
                        </a></li></ul></li><li><span class="label">30.
              </span><a name="pone.0001809-Pan1" id="pone.0001809-Pan1"></a>Pan L, Jia Z, Chen L, Fu E, Li G (2005) Effect of anti-tuberculosis therapy on liver function of pulmonary tuberculosis patients infected with hepatitis B virus. World J Gastroenterol  11: 2518–2521.  <ul class="find" data-citedArticleID="1075744"><li><a href="http://www.crossref.org/guestquery/?auth2=&amp;atitle2=Effect+of+anti-tuberculosis+therapy+on+liver+function+of+pulmonary+tuberculosis+patients+infected+with+hepatitis+B+virus.&amp;auth=&amp;atitle=Effect+of+anti-tuberculosis+therapy+on+liver+function+of+pulmonary+tuberculosis+patients+infected+with+hepatitis+B+virus." target="_new" title="Go to article in CrossRef">
                          View Article
                        </a></li><li><a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&amp;cmd=Search&amp;doptcmdl=Citation&amp;defaultField=Title+Word&amp;term=Effect+of+anti-tuberculosis+therapy+on+liver+function+of+pulmonary+tuberculosis+patients+infected+with+hepatitis+B+virus." target="_new" title="Go to article in PubMed">
                          PubMed/NCBI
                        </a></li><li><a href="http://scholar.google.com/scholar?hl=en&amp;safe=off&amp;q=%22Effect+of+anti-tuberculosis+therapy+on+liver+function+of+pulmonary+tuberculosis+patients+infected+with+hepatitis+B+virus.%22" target="_new" title="Go to article in Google Scholar">
                          Google Scholar
                        </a></li></ul></li><li><span class="label">31.
              </span><a name="pone.0001809-Lee1" id="pone.0001809-Lee1"></a>Lee BH, Koh W, Choi MS, Suh GY, Chung MP, et al.  (2005) Inactive Hepatitis B Surface Antigen Carrier State and Hepatotoxicity During Antituberculosis Chemotherapy. Chest  127: 1304–1311.  <ul class="find" data-citedArticleID="1075738" data-doi="10.1378/chest.127.4.1304"><li><a href="http://dx.doi.org/10.1378/chest.127.4.1304" target="_new" title="Go to article in CrossRef">
                          View Article
                        </a></li><li><a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&amp;cmd=Search&amp;doptcmdl=Citation&amp;defaultField=Title+Word&amp;term=Inactive+Hepatitis+B+Surface+Antigen+Carrier+State+and+Hepatotoxicity+During+Antituberculosis+Chemotherapy." target="_new" title="Go to article in PubMed">
                          PubMed/NCBI
                        </a></li><li><a href="http://scholar.google.com/scholar?hl=en&amp;safe=off&amp;q=%22Inactive+Hepatitis+B+Surface+Antigen+Carrier+State+and+Hepatotoxicity+During+Antituberculosis+Chemotherapy.%22" target="_new" title="Go to article in Google Scholar">
                          Google Scholar
                        </a></li></ul></li></ol></div>

  </div>

      <input type="hidden" class="assetSize" name="info:doi/10.1371/journal.pone.0001809.XML" value="74828"/>
      <input type="hidden" class="assetSize" name="info:doi/10.1371/journal.pone.0001809.PDF" value="90926"/>
      <input type="hidden" class="assetSize" name="info:doi/10.1371/journal.pone.0001809.t001.PNG_L" value="139343"/>
      <input type="hidden" class="assetSize" name="info:doi/10.1371/journal.pone.0001809.t001.PNG_M" value="138873"/>
      <input type="hidden" class="assetSize" name="info:doi/10.1371/journal.pone.0001809.t001.PNG_S" value="19995"/>
      <input type="hidden" class="assetSize" name="info:doi/10.1371/journal.pone.0001809.t001.TIF" value="683036"/>
      <input type="hidden" class="assetSize" name="info:doi/10.1371/journal.pone.0001809.t001.PNG_I" value="69246"/>
      <input type="hidden" class="assetSize" name="info:doi/10.1371/journal.pone.0001809.t002.PNG_L" value="163593"/>
      <input type="hidden" class="assetSize" name="info:doi/10.1371/journal.pone.0001809.t002.PNG_M" value="93823"/>
      <input type="hidden" class="assetSize" name="info:doi/10.1371/journal.pone.0001809.t002.PNG_S" value="19096"/>
      <input type="hidden" class="assetSize" name="info:doi/10.1371/journal.pone.0001809.t002.TIF" value="947864"/>
      <input type="hidden" class="assetSize" name="info:doi/10.1371/journal.pone.0001809.t002.PNG_I" value="100007"/>
      <input type="hidden" class="assetSize" name="info:doi/10.1371/journal.pone.0001809.t003.PNG_L" value="86366"/>
      <input type="hidden" class="assetSize" name="info:doi/10.1371/journal.pone.0001809.t003.PNG_M" value="98768"/>
      <input type="hidden" class="assetSize" name="info:doi/10.1371/journal.pone.0001809.t003.PNG_S" value="16048"/>
      <input type="hidden" class="assetSize" name="info:doi/10.1371/journal.pone.0001809.t003.TIF" value="509730"/>
      <input type="hidden" class="assetSize" name="info:doi/10.1371/journal.pone.0001809.t003.PNG_I" value="39509"/>
      <input type="hidden" class="assetSize" name="info:doi/10.1371/journal.pone.0001809.t004.PNG_L" value="70776"/>
      <input type="hidden" class="assetSize" name="info:doi/10.1371/journal.pone.0001809.t004.PNG_M" value="94734"/>
      <input type="hidden" class="assetSize" name="info:doi/10.1371/journal.pone.0001809.t004.PNG_S" value="14792"/>
      <input type="hidden" class="assetSize" name="info:doi/10.1371/journal.pone.0001809.t004.TIF" value="385740"/>
      <input type="hidden" class="assetSize" name="info:doi/10.1371/journal.pone.0001809.t004.PNG_I" value="30236"/>

</div>
<div class="sidebar">

  <div class="article-actions cf">
      <div class="download">
        <span class="btn"><a href="/article/fetchObject.action?uri=info%3Adoi%2F10.1371%2Fjournal.pone.0001809&amp;representation=PDF" title="Download" target="_blank">Download PDF</a></span>
      </div>
      <div class="btn-reveal dropdown">
        <div class="dropdown-icon">
          <span class="btn">&nbsp;</span>
        </div>

        <div class="content">
          <ul class="bullet">
            <li><a href="/article/citationList.action?articleURI=info%3Adoi%2F10.1371%2Fjournal.pone.0001809" title="Download citations">Citation</a></li>
            <li><a href="/article/fetchObjectAttachment.action?uri=info%3Adoi%2F10.1371%2Fjournal.pone.0001809&amp;representation=XML" title="Download article XML">XML</a></li>
          </ul>
        </div>
      </div> <!-- end btn-reveal dropdown-->


    <div class="btn-reveal flt-l">
        <span class="btn">Print</span>
        <div class="content">
            <ul class="bullet">
                <li id="print-article"><a href="#" onclick="if(typeof(_gaq) != 'undefined'){ _gaq.push(['_trackEvent','Article', 'Print', 'Click']); } window.print(); return false;" title="Print Article">Print article</a></li>
                <li>
                  <a href="https://www.odysseypress.com/onlinehost/reprint_order.php?type=A&page=0&journal=7&doi=10.1371/journal.pone.0001809&volume=&issue=&title=Anti-Tuberculosis Therapy-Induced Hepatotoxicity among Ethiopian HIV-Positive and Negative Patients&author_name=Getnet%20Yimer%2C%20Getachew%20Aderaye%2C%20Wondwossen%20Amogne%2C%20Eyasu%20Makonnen%2C%20Eleni%20Aklillu%2C%20Lars%20Lindquist%2C%20Lawrence%20Yamuah%2C%20Beniyam%20Feleke%2C%20Abraham%20Aseffa&start_page=1&end_page=5" title="Odyssey Press">EzReprint</a>
                </li>
            </ul>
        </div>
    </div>

    <div class="btn-reveal flt-r">
        <span class="btn">Share</span>
        <div class="content">
            <ul class="social">
                <li><a href="http://www.reddit.com/submit?url=http%3A%2F%2Fdx.plos.org%2F10.1371%2Fjournal.pone.0001809" target="_blank" title="Submit to Reddit"><img src="/images/icon.reddit.16.png" width="16" height="16" alt="Reddit">Reddit</a></li>

                <li><a href="https://plus.google.com/share?url=http%3A%2F%2Fdx.plos.org%2F10.1371%2Fjournal.pone.0001809" target="_blank" title="Share on Google+"><img src="/images/icon.gplus.16.png" width="16" height="16" alt="Google+">Google+</a></li>

                <li><a href="http://www.stumbleupon.com/submit?url=http%3A%2F%2Fwww.plosone.org%2Farticle%2Finfo%253Adoi%252F10.1371%252Fjournal.pone.0001809" target="_blank" title="Add to StumbleUpon"><img src="/images/icon.stumble.16.png" width="16" height="16" alt="StumbleUpon">StumbleUpon</a></li>

                <li><a href="http://www.facebook.com/share.php?u=http%3A%2F%2Fdx.plos.org%2F10.1371%2Fjournal.pone.0001809&amp;t=Anti-Tuberculosis%20Therapy-Induced%20Hepatotoxicity%20among%20Ethiopian%20HIV-Positive%20and%20Negative%20Patients" target="_blank" title="Share on Facebook"><img src="/images/icon.fb.16.png" width="16" height="16" alt="Facebook">Facebook</a></li>

                <li><a href="http://www.linkedin.com/shareArticle?url=http%3A%2F%2Fdx.plos.org%2F10.1371%2Fjournal.pone.0001809&title=Anti-Tuberculosis%20Therapy-Induced%20Hepatotoxicity%20among%20Ethiopian%20HIV-Positive%20and%20Negative%20Patients&summary=Checkout%20this%20article%20I%20found%20at%20PLOS" target="_blank" title="Add to LinkedIn"><img src="/images/icon.linkedin.16.png" width="16" height="16" alt="Mendeley">LinkedIn</a></li>

                <li><a href="http://www.citeulike.org/posturl?url=http%3A%2F%2Fdx.plos.org%2F10.1371%2Fjournal.pone.0001809&amp;title=Anti-Tuberculosis%20Therapy-Induced%20Hepatotoxicity%20among%20Ethiopian%20HIV-Positive%20and%20Negative%20Patients" target="_blank" title="Add to CiteULike"><img src="/images/icon.cul.16.png" width="16" height="16" alt="CiteULike">CiteULike</a></li>

                <li><a href="http://www.mendeley.com/import/?url=http%3A%2F%2Fdx.plos.org%2F10.1371%2Fjournal.pone.0001809" target="_blank" title="Add to Mendeley"><img src="/images/icon.mendeley.16.png" width="16" height="16" alt="Mendeley">Mendeley</a></li>

                <li><a href="https://www.pubchase.com/library?add_aid=10.1371%2Fjournal.pone.0001809&amp;source=plos" target="_blank" title="Add to PubChase"><img src="/images/icon.pc.16.png" width="16" height="16" alt="PubChase">PubChase</a></li>


                <script type="text/javascript">
                    // replace tweet with one that's pre-shortened to 140 chars
                    function truncateTweetText() {
                        var twtTitle = 'Anti-Tuberculosis Therapy-Induced Hepatotoxicity among Ethiopian HIV-Positive and Negative Patients';
                        var twtUrl = 'http://dx.plos.org/10.1371/journal.pone.0001809';
                        // all URLs posted to twitter get auto-shortened to 20 chars.
                        var maxLength = 140 - (20 + 1);
                        // truncate the title to include space for twtTag and ellipsis (here, 10 = tag length + space + ellipsis)
                        if (twtTitle.length > maxLength) { twtTitle = twtTitle.substr(0, (maxLength - 10)) + '...'; }
                        // set the href to use the shortened tweet
                        $('#twitter-share-link').prop('href', 'http://twitter.com/intent/tweet?text=' + encodeURIComponent('#PLOSONE: ' + twtTitle + ' ' + twtUrl));
                    }
                </script>
                <li><a href="http://twitter.com/intent/tweet?text=#PLOSONE%3A%20Anti-Tuberculosis%20Therapy-Induced%20Hepatotoxicity%20among%20Ethiopian%20HIV-Positive%20and%20Negative%20Patients http%3A%2F%2Fdx.plos.org%2F10.1371%2Fjournal.pone.0001809" onclick="truncateTweetText();" target="_blank" title="Share on Twitter" id="twitter-share-link"><img src="/images/icon.twtr.16.png" width="16" height="16" alt="Twitter">Twitter</a></li>

                <li><a href="/article/email/info%3Adoi%2F10.1371%2Fjournal.pone.0001809" title="Email this article"><img src="/images/icon.email.16.png" width="16" height="16" alt="Email">Email</a></li>
            </ul>
        </div>
    </div><!--end btn-reveal flt-r-->
</div><!-- end article-actions-->

<!-- begin Crossmark -->

<a id="open-crossmark" href="#" style="margin-top: -28px; display:block"><img style="border: 0; display: none;
 padding: 10px 0 18px 0;"  id="crossmark-icon" src="/images/logo-crossmark-bw.png" /></a>
<div id="crossmark-dialog" style="display: none;" title="">
    <!-- the external CrossMark data is loaded inside this iframe -->
    <iframe id="crossmark-dialog-frame" frameborder="0"></iframe>
</div>

<!-- end crossmark -->


<div class="block" id="subject-area-sidebar-block">
    <div class="header">
        <h3>Subject Areas</h3><div title="More information" id="subject-area-sidebar-block-help-icon"><img align="right"
                                                                                                           alt="info" src="/images/button_info.png"/><div id="subject-area-sidebar-block-help"><img align="right"
                                                                                                                                                                                                    src="/images/button_info.png"/><p>
        <b>We want your feedback.</b> Do these subject areas make sense for this article? If not, click the flag
        next to the incorrect subject area and we will review it. Thanks for your help!
    </p></div></div>
    </div>


    <ul id="subject-area-sidebar-list">
















          <li>
              <a href="/search/advanced?unformattedQuery=subject%3A%22Drug+research+and+development%22" title="Search for articles in the subject area:'Drug research and development'"><div class="flagText">Drug research and development</div></a>
              <div data-categoryid="18001" data-articleid="26442"
                   data-categoryname="Drug research and development"
                   class="flagImage" title="Flag 'Drug research and development' as inappropriate"></div>
          </li>
          <li>
              <a href="/search/advanced?unformattedQuery=subject%3A%22Drug+therapy%22" title="Search for articles in the subject area:'Drug therapy'"><div class="flagText">Drug therapy</div></a>
              <div data-categoryid="18461" data-articleid="26442"
                   data-categoryname="Drug therapy"
                   class="flagImage" title="Flag 'Drug therapy' as inappropriate"></div>
          </li>
          <li>
              <a href="/search/advanced?unformattedQuery=subject%3A%22HIV%22" title="Search for articles in the subject area:'HIV'"><div class="flagText">HIV</div></a>
              <div data-categoryid="42663" data-articleid="26442"
                   data-categoryname="HIV"
                   class="flagImage" title="Flag 'HIV' as inappropriate"></div>
          </li>
          <li>
              <a href="/search/advanced?unformattedQuery=subject%3A%22HIV+diagnosis+and+management%22" title="Search for articles in the subject area:'HIV diagnosis and management'"><div class="flagText">HIV diagnosis and management</div></a>
              <div data-categoryid="18941" data-articleid="26442"
                   data-categoryname="HIV diagnosis and management"
                   class="flagImage" title="Flag 'HIV diagnosis and management' as inappropriate"></div>
          </li>
          <li>
              <a href="/search/advanced?unformattedQuery=subject%3A%22HIV+infections%22" title="Search for articles in the subject area:'HIV infections'"><div class="flagText">HIV infections</div></a>
              <div data-categoryid="47749" data-articleid="26442"
                   data-categoryname="HIV infections"
                   class="flagImage" title="Flag 'HIV infections' as inappropriate"></div>
          </li>
          <li>
              <a href="/search/advanced?unformattedQuery=subject%3A%22Isoniazid%22" title="Search for articles in the subject area:'Isoniazid'"><div class="flagText">Isoniazid</div></a>
              <div data-categoryid="24257" data-articleid="26442"
                   data-categoryname="Isoniazid"
                   class="flagImage" title="Flag 'Isoniazid' as inappropriate"></div>
          </li>
          <li>
              <a href="/search/advanced?unformattedQuery=subject%3A%22Liver+function+tests%22" title="Search for articles in the subject area:'Liver function tests'"><div class="flagText">Liver function tests</div></a>
              <div data-categoryid="27769" data-articleid="26442"
                   data-categoryname="Liver function tests"
                   class="flagImage" title="Flag 'Liver function tests' as inappropriate"></div>
          </li>
          <li>
              <a href="/search/advanced?unformattedQuery=subject%3A%22Tuberculosis%22" title="Search for articles in the subject area:'Tuberculosis'"><div class="flagText">Tuberculosis</div></a>
              <div data-categoryid="47969" data-articleid="26442"
                   data-categoryname="Tuberculosis"
                   class="flagImage" title="Flag 'Tuberculosis' as inappropriate"></div>
          </li>
    </ul>
</div>

<div class="ad">
    <div class="title">Advertisement</div>






  <iframe id='a0852f54' name='a0852f54'
    src='http://ads.plos.org/www/delivery/afr.php?zoneid=381&amp;cb=5657'
    frameborder='0' scrolling='no' width='160' height='600'>
    <a href='http://ads.plos.org/www/delivery/ck.php?n=a0852f54&amp;cb=17'
      target='_top'><img src='http://ads.plos.org/www/delivery/avw.php?zoneid=381&amp;cb=3817&amp;n=a0852f54'
      border='0' alt=''/>
    </a>
  </iframe>



</div>

<div id="twitter-alm-timeline" class="twitter-alm-timeline"></div>


</div><!-- sidebar -->
    </div>
  </div>
</div>
<script src="http://wl.figshare.com/static/p_widget.js" type="text/javascript"></script><div id="pageftr">
  <div class="ftr-cols cf">
    <div class="col col-1">
      <img src="/images/logo-plos-footer.png" alt="PLOS Logo" class="logo" />
      <p><a href="/static/releaseNotes">Ambra 2.9.16</a> Managed Colocation provided <br />by <a href="http://www.isc.org/">Internet Systems Consortium</a>.<p>
      <div class="nav nav-aux">
        <a href="/static/privacy">Privacy Policy</a> |
        <a href="/static/terms">Terms of Use</a> |
        <a href="http://www.plos.org/advertise/">Advertise</a> |
        <a href="http://www.plos.org/about/media-inquiries/">Media Inquiries</a>
      </div>
    </div>
    <div class="col col-2">
      <p><a href="http://www.plos.org/publications/journals/">Publications</a></p>
      <div class="nav">
        <ul>
          <li><a href="http://www.plosbiology.org">PLOS Biology</a></li>
          <li><a href="http://www.plosmedicine.org">PLOS Medicine</a></li>
          <li><a href="http://www.ploscompbiol.org">PLOS Computational Biology</a></li>
          <li><a href="http://currents.plos.org">PLOS Currents</a></li>
          <li><a href="http://www.plosgenetics.org">PLOS Genetics</a></li>
          <li><a href="http://www.plospathogens.org">PLOS Pathogens</a></li>
          <li><a href="http://www.plosone.org">PLOS ONE</a></li>
          <li><a href="http://www.plosntds.org">PLOS Neglected Tropical Diseases</a></li>
        </ul>
      </div>
    </div>
    <div class="col col-3">
      <div class="nav">
        <p><a href="http://www.plos.org">plos.org</a></p>
        <p><a href="http://blogs.plos.org">Blogs</a></p>
        <p><a href="http://www.ploscollections.org">Collections</a></p>
        <p><a href="/feedback/new">Send us feedback</a></p>

        <p>California (US) corporation #C2354500, based in San Francisco</p>
      </div>
    </div>
  </div>
</div><!-- pageftr -->

</div><!-- end page-wrap, this div is in header.ftl -->
<script type="text/javascript" src="/javascript/jquery-1.8.1-min.js?v=Tm7VCOzZz3lE03ghpkS6SWkHbyI"></script>
<script type="text/javascript" src="/javascript/ga-min.js?v=lNQ4gt8QcPDatjsdOFl_FGpPhLY"></script>
<script type="text/javascript" src="/javascript/jquery.hoverIntent-min.js?v=mRiGNYY9cIXxVb8u0K_MdW7hHnc"></script>
<script type="text/javascript" src="/javascript/jquery.placeholder-min.js?v=21Pn56Ur9h1N4K4VZDa0nqI3Pxo"></script>
<script type="text/javascript" src="/javascript/jquery.jsonp-2.4.0-min.js?v=lqTpzoHfSq3I5Ygo01qq5WankEo"></script>
<script type="text/javascript" src="/javascript/jquery-ui-1.9.2.custom-min.js?v=raSSlfNO0YsV5uUpAKmTB9n5VTc"></script>
<script type="text/javascript" src="/javascript/jquery.tooltip-min.js?v=cw+6Smh+mdryIA25xvqIvHMrnZM"></script>
<script type="text/javascript" src="/javascript/jquery.uniform-min.js?v=kYUAnX6W2W_2fK3RIuQ2m_YFG9U"></script>
<script type="text/javascript" src="/javascript/jquery.pjax-min.js?v=939kLBjL5_YKbx71T1RHjYaD4l8"></script>
<script type="text/javascript" src="/javascript/imagesloaded-min.js?v=XeuAp8Gc3mvQUo+wZCSF8ttPwvw"></script>
<script type="text/javascript" src="/javascript/figviewer-min.js?v=yPUa0sUQ_iHkI+IRv2i9bjyZJFo"></script>
<script type="text/javascript" src="/javascript/global-min.js?v=0Q3PwjeaWtXYDnqIsQvnL_ou0qs"></script>
<script type="text/javascript" src="/javascript/jquery.touchswipe-min.js?v=huaek_e6HqTduvCNAN91dJolTyw"></script>
<script type="text/javascript" src="/javascript/jquery.base64-min.js?v=VwV1zeVqKZj5FCAdlK0q5NRxbBg"></script>
<script type="text/javascript" src="/javascript/alm-min.js?v=Y5gm6B0b4Kx2YHNObNrgEeBgXlY"></script>
<script type="text/javascript" src="/javascript/taxonomy-browser-min.js?v=vBVMuDMYkGJCXIUxLe35GoyiJNw"></script>
<script type="text/javascript" src="/javascript/jquery.filterize-min.js?v=j0ZKVnHyk2nhFy8eIuNJkp7xaM0"></script>
<script type="text/javascript" src="/javascript/plosone-min.js?v=TK4H4arL_XBSwwJq+K1N3kqYfAI"></script>
<script type="text/javascript" src="/javascript/twitter-min.js?v=xKgcxLsQFXy+at1ao1NVke8nFlM"></script>
<script type="text/javascript" src="/javascript/crossmark.1.4-min.js?v=3FO4k0SjwTaGNnKGNSqthar1080"></script>
<script type="text/javascript">
  var _sf_async_config={uid:16579,domain:"plosone.org"};
  (function(){
    function loadChartbeat() {
      window._sf_endpt=(new Date()).getTime();
      var e = document.createElement('script');
      e.setAttribute('language', 'javascript');
      e.setAttribute('type', 'text/javascript');
      e.setAttribute('src',
          (("https:" == document.location.protocol) ? "https://a248.e.akamai.net/chartbeat.download.akamai.com/102508/" : "http://static.chartbeat.com/") +
              "js/chartbeat.js");
      document.body.appendChild(e);
    }
    var oldonload = window.onload;
    window.onload = (typeof window.onload != 'function') ?
        loadChartbeat : function() { oldonload(); loadChartbeat(); };
  })();
</script>
<!-- <script type="application/javascript" src="http://crossmark.crossref.org/javascripts/v1.3/crossmark.min.js"></script> -->

</body>
</html>
